

CITATION REPORT

List of articles citing

Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons

DOI: 10.1073/pnas.95.11.6460

Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6460-4.

Source: <https://exaly.com/paper-pdf/29798968/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1103	Molecular genetics of the caveolin gene family: implications for human cancers, diabetes, Alzheimer disease, and muscular dystrophy. 1998 , 63, 1578-87		159
1102	Potential therapeutic targets for Alzheimer's disease. 1998 , 2, 157-179		5
1101	Protein and lipid sorting from the trans-Golgi network to the plasma membrane in polarized cells. 1998 , 9, 503-9		156
1100	Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. 1998 , 252, 711-5		271
1099	Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998 , 95, 13266-71	11.5	117
1098	Cholesterol balance and metabolism in mice with loss of function of Niemann-Pick C protein. 1999 , 276, E336-44		50
1097	The amyloid precursor protein interacts with G α heterotrimeric protein within a cell compartment specialized in signal transduction. 1999 , 19, 1717-27		100
1096	Caveolin-3 upregulation activates beta-secretase-mediated cleavage of the amyloid precursor protein in Alzheimer's disease. 1999 , 19, 6538-48		71
1095	Distribution of Presenilins and Amyloid Precursor Protein (APP) in Detergent-Insoluble Membrane Domains. 2000 , 32, 345-60		1
1094	Binding and selective detection of the secretory N-terminal domain of the Alzheimer amyloid precursor protein on cell surfaces. 1999 , 47, 373-82		24
1093	Exogenous administration of gangliosides displaces GPI-anchored proteins from lipid microdomains in living cells. 1999 , 10, 3187-96		82
1092	Amyloid and lipids in the pathology of Alzheimer disease. 1999 , 6, 136-45		57
1091	Cholesterol-dependent localization of NAP-22 on a neuronal membrane microdomain (raft). 1999 , 274, 21369-74		84
1090	Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture. 1999 , 274, 15110-4		91
1089	A review of recent applications of cyclodextrins for drug discovery. 1999 , 9, 1697-1717		29
1088	Glycosylphosphatidylinositol-anchored proteins play an important role in the biogenesis of the Alzheimer's amyloid beta-protein. 1999 , 274, 26810-4		43
1087	Discrete localizations of hedgehog signalling components in the developing and adult rat nervous system. 1999 , 11, 3199-214		130

1086	Regulation of amyloid precursor protein cleavage. 1999 , 72, 443-60	170
1085	Membrane raft microdomains mediate front-rear polarity in migrating cells. 1999 , 18, 6211-20	278
1084	Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease. 1999 , 34, 225-34	108
1083	Fibrillar Alzheimer's amyloid peptide A β (1-42) stimulates low density lipoprotein binding and cell association, free radical production and cell cytotoxicity in PC12 cells. 1999 , 33, 510-6	17
1082	Alzheimer's Disease. 1999 ,	
1081	Rationalizing a pharmacological intervention on the amyloid precursor protein metabolism. 1999 , 20, 418-23	43
1080	Central amyloidosis in Alzheimer's disease: Biology of the production of the amyloid peptide. 1999 , 9, 140-141	
1079	Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). 1999 , 16, 145-56	320
1078	Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. 1999 , 344, 23-30	96
1077	Copper inhibits A β amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. 1999 , 344, 461-467	144
1076	Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. 1999 , 344, 23	29
1075	Copper inhibits A β amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. 1999 , 344, 461	61
1074	CHAPTER 5.6 Identification and functional analysis of genes and genetic risk factors in Alzheimer's disease. 1999 , 841-862	
1073	The role of cholesterol in the biosynthesis of beta-amyloid. 1999 , 10, 1699-705	313
1072	Caveolins, liquid-ordered domains, and signal transduction. 1999 , 19, 7289-304	913
1071	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. 2000 , 348, 307	38
1070	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. 2000 , 348, 307-313	89
1069	Clinical issues in current drug therapy for dementia. 2000 , 14 Suppl 1, S103-8	9

1068	Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. 2000 , 11, 1959-62	121
1067	Link between heart disease, cholesterol, and Alzheimer's disease: a review. 2000 , 50, 287-90	108
1066	Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein. 2000 , 50, 316-24	37
1065	A unifying hypothesis of Alzheimer's disease. III. Risk factors. 2000 , 15, 1-70	32
1064	Caveolins and cellular cholesterol balance. 2000 , 1, 212-7	109
1063	Apolipoprotein E varepsilon4 allele has an impact on vascular reactivity in Alzheimer's disease. 2000 , 31, 221-231	5
1062	Age-related structural and functional changes of brain mitochondria. 2000 , 28, 329-38	62
1061	A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation. 2000 , 79, 905-14	61
1060	Factors influencing the processing and function of the amyloid beta precursor protein--a potential therapeutic target in Alzheimer's disease?. 2000 , 86, 111-45	36
1059	Interaction of amyloid beta-protein with anionic phospholipids: possible involvement of Lys28 and C-terminus aliphatic amino acids. 2000 , 25, 423-9	91
1058	Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. 2000 , 1, 530-5	190
1057	Proteolysis in Alzheimer's disease. Can plasmin tip the balance?. 2000 , 1, 477-8	20
1056	Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. 2000 , 19, 141-8	97
1055	Pathogens, toxins, and lipid rafts. 2000 , 212, 8-14	17
1054	Molecular basis of Alzheimer's disease. 2000 , 57, 705-15	68
1053	Serum levels of coenzyme Q10 in patients with Alzheimer's disease. 2000 , 107, 233-9	29
1052	. 2000 ,	
1051	Inhibition of sonic hedgehog autoprocessing in cultured mammalian cells by sterol deprivation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 7307-12	11.5 55

1050	Embryonic striatal neurons from niemann-pick type C mice exhibit defects in cholesterol metabolism and neurotrophin responsiveness. 2000 , 275, 20179-87	63
1049	The molecular and genetic basis of AD: the end of the beginning: the 2000 Wartenberg lecture. 2000 , 54, 2045-54	126
1048	Testosterone reduces neuronal secretion of Alzheimer's beta-amyloid peptides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 1202-5	11.5 258
1047	Altered cholesterol metabolism in human apolipoprotein E4 knock-in mice. 2000 , 9, 353-61	62
1046	Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 2000 , 57, 1439-43	1234
1045	Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer disease?. 2000 , 57, 1410-2	68
1044	Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. 2000 , 7, 321-31	847
1043	Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. 2000 , 157, 2093-9	101
1042	Neuronal localization of sterol regulatory element binding protein-1 in the rodent and primate brain: a light and electron microscopic immunocytochemical study. 2000 , 97, 143-53	32
1041	7alpha-Hydroperoxycholesterol causes CNS neuronal cell death. 2000 , 36, 507-12	8
1040	The role of cerebral ischemia in Alzheimer's disease. 2000 , 21, 321-30	439
1039	Oligomerization and fibril assembly of the amyloid-beta protein. 2000 , 1502, 31-43	70
1038	Neuronal models to study amyloid precursor protein expression and processing in vitro. 2000 , 1502, 53-62	3
1037	Amyloid precursor protein in unique cholesterol-rich microdomains different from caveolae-like domains. 2000 , 1483, 81-90	30
1036	GPI-Anchored Proteins and Glycosphingolipid-Rich Rafts: Platforms for Adhesion and Signaling. 2000 , 6, 271-284	9
1035	The effect of sterol structure on membrane lipid domains reveals how cholesterol can induce lipid domain formation. 2000 , 39, 843-9	439
1034	How cells handle cholesterol. 2000 , 290, 1721-6	970
1033	Apoptosis modulators in the therapy of neurodegenerative diseases. 2000 , 9, 747-64	70

1032	Use of statins in CNS disorders. 2001 , 187, 81-9	101
1031	Cholesterol, a modulator of membrane-associated Abeta-fibrillogenesis and neurotoxicity. 2001 , 311, 723-34	194
1030	A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. 2001 , 8, 890-9	462
1029	On the turnover of brain cholesterol in patients with Alzheimer's disease. Abnormal induction of the cholesterol-catabolic enzyme CYP46 in glial cells. 2001 , 314, 45-8	160
1028	Cholesterol, A beta and Alzheimer's disease. 2001 , 24, S45-8	82
1027	Cholesterol, A and Alzheimer's disease. 2001 , 24, 45-48	61
1026	Association of membrane-bound amyloid precursor protein APP with the apolipoprotein E receptor LRP. 2001 , 87, 238-45	52
1025	Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. 2001 , 22, 217-27	223
1024	High cholesterol diet down regulates the activity of activator protein-1 but not nuclear factor-kappa B in rabbit brain. 2001 , 68, 1495-503	13
1023	Complex gangliosides as cell surface inhibitors for the ecto-NAD ⁺ glycohydrolase of CD38. 2001 , 40, 888-95	19
1022	Current theories for the molecular and cellular pathogenesis of Alzheimers disease. 2001 , 2001, 1-11	4
1021	Cholesterol metabolism in the brain. 2001 , 12, 105-12	644
1020	Statins for the reduction of risk of Alzheimer's disease. 2001 , CD003160	30
1019	Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. 2001 , 12, 883-7	61
1018	3-hydroxy-3-methylglutaryl-coenzyme A reductase mRNA in Alzheimer and control brain. 2001 , 12, 2935-8	20
1017	Alzheimer disease therapeutics. 2001 , 60, 923-8	33
1016	The Amyloid Precursor Protein V717I Mutation Increases Susceptibility to Cell Death in a Cholesterol-dependent Manner. 469-477	
1015	Alzheimer's disease: molecular concepts and therapeutic targets. 2001 , 88, 261-7	42

1014	Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. 2001 , 108, 1051-64	54
1013	Characterization of detergent-insoluble complexes containing the familial Alzheimer's disease-associated presenilins. 1999 , 72, 1534-43	61
1012	Collagen VI deficiency in Ullrich's disease. 2001 , 49, 544-544	21
1011	Cathepsin D polymorphism not associated with Alzheimer's disease in Japanese. 2001 , 49, 544-545	15
1010	Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231. 2001 , 49, 545-546	89
1009	Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins. 2001 , 49, 546-547	35
1008	Correction. 2001 , 49, 547-547	
1007	Intracellular cholesterol and phospholipid trafficking: comparable mechanisms in macrophages and neuronal cells. 2001 , 26, 1045-68	16
1006	Alzheimer's amyloid-beta as a preventive antioxidant for brain lipoproteins. 2001 , 21, 299-315	19
1005	Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. 2001 , 3, 905-12	393
1004	Caveolae and the caveolins in human disease. 2001 , 49, 325-35	19
1003	Pharmacogenomics of neurodegenerative diseases. 2001 , 413, 11-29	42
1002	Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. 2001 , 11, 1288-93	282
1001	Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. 2001 , 31, 1120-31	137
1000	Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. 2001 , 6, 1049-1055	56
999	A fluid connection: cholesterol and A β . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5371-3	11.5 175
998	Reduction in cholesterol and sialic acid content protects cells from the toxic effects of beta-amyloid peptides. 2001 , 276, 42027-34	80
997	Alzheimer's Disease: Physiological and Pathogenetic Role of the Amyloid Precursor Protein (APP), its A β Amyloid Domain and Free A β Amyloid Peptide. 2001 , 97-117	3

996	Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. 2001 , 276, 24985-90		305
995	Nutritional factors and Alzheimer's disease. 2001 , 56, M675-80		39
994	Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study. 2001 , 56, 1683-9		569
993	Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5815-20	11.5	677
992	Cross-talk between caveolae and glycosylphosphatidylinositol-rich domains. 2001 , 276, 30729-36		77
991	Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 5856-61	11.5	949
990	Association of FcgammaRII with low-density detergent-resistant membranes is important for cross-linking-dependent initiation of the tyrosine phosphorylation pathway and superoxide generation. 2001 , 167, 5814-23		56
989	Segregation of leading-edge and uropod components into specific lipid rafts during T cell polarization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 9642-7	11.5	428
988	LRP: a multifunctional scavenger and signaling receptor. 2001 , 108, 779-784		759
987	Cholesterol and Alzheimer's disease: is there a link?. 2001 , 57, 1089-93		228
986	Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress. 2001 , 20, 7-15		81
985	Cellular Peptidases in Immune Functions and Diseases 2. 2002 ,		
984	The role of proteolysis in Alzheimer's disease. 2000 , 477, 379-90		33
983	Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. 2002 , 277, 38772-80		47
982	Plasma membrane cholesterol controls the cytotoxicity of Alzheimer's disease AbetaP (1-40) and (1-42) peptides. 2002 , 16, 1526-36		177
981	Induction of the cholesterol transporter ABCA1 in central nervous system cells by liver X receptor agonists increases secreted Abeta levels. 2002 , 277, 48508-13		122
980	Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. 2002 , 16, 1677-9		102
979	A combination of three distinct trafficking signals mediates axonal targeting and presynaptic clustering of GAD65. 2002 , 158, 1229-38		62

978	Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. 2002 , 59, 213-6	145
977	Serum lipoprotein levels, statin use, and cognitive function in older women. 2002 , 59, 378-84	367
976	The cerebellum may be directly involved in cognitive functions. 2002 , 59, 790-1; author reply 791	1
975	No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. 2002 , 33, 896-900	10
974	Einsatz der Statine in der Neurologie. 2002 , 29, 254-261	2
973	Apolipoprotein E (ApoE) isoform-dependent lipid release from astrocytes prepared from human ApoE3 and ApoE4 knock-in mice. 2002 , 277, 29919-26	153
972	Spontaneous intracranial hypotension causing reversible frontotemporal dementia. 2002 , 59, 787; author reply 787	9
971	Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. 2002 , 24, 248-68	46
970	Cholesterol and neuropathologic markers of AD: a population-based autopsy study. 2002 , 59, 788-9; author reply 789	2
969	Will neurology residents with large student loan debts become academicians?. 2002 , 59, 789; author reply 789	0
968	Comparison of rizatriptan and other triptans on stringent measures of efficacy. 2002 , 59, 787; author reply 788	2
967	The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. 2002 , 57, M414-8	128
966	Risk factors for Alzheimer's disease: role of multiple antioxidants, non-steroidal anti-inflammatory and cholinergic agents alone or in combination in prevention and treatment. 2002 , 21, 506-22	57
965	Multiple sclerosis distribution in northern Sardinia: spatial cluster analysis of prevalence. 2002 , 59, 790; author reply 790	
964	Profile of cholesterol-related sterols in aged amyloid precursor protein transgenic mouse brain. 2002 , 43, 1078-85	115
963	Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. 2002 , 277, 49631-7	140
962	Statins in the prevention and treatment of Alzheimer disease. 2002 , 16, 131-6	67
961	Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. 2002 , 13, 455-9	196

960	Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. 2002 , 59, 1257-8	104
959	Statins and menopausal health. 2002 , 8, 141-6	3
958	Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease: potential for pharmacological intervention. 2002 , 16, 435-44	57
957	Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. 2002 , 9, 11-23	365
956	Interactions of A beta with endogenous anti-inflammatory agents: a basis for chronic neuroinflammation in Alzheimer's disease. 2002 , 10, 187-200	6
955	ApoE genotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: evidence from a peripheral model. 2002 , 12, 195-200	43
954	Cholesterol attenuates the membrane perturbing properties of beta-amyloid peptides. 2002 , 9, 149-59	23
953	Association of amyloid- β peptide with membrane surfaces monitored by solid state NMR. 2002 , 4, 5524-5530	37
952	Lipoprotein receptors in the nervous system. 2002 , 71, 405-34	346
951	Biogenesis and metabolism of Alzheimer's disease Abeta amyloid peptides. 2002 , 23, 1285-97	132
950	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. 2002 , 23, 485-508	159
949	Brain membrane cholesterol domains, aging and amyloid beta-peptides. 2002 , 23, 685-94	124
948	Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease. 2002 , 23, 324-30	59
947	Inhibition of intracellular cholesterol transport alters presenilin localization and amyloid precursor protein processing in neuronal cells. 2002 , 22, 1679-89	211
946	Nutrition and cognition in older persons. 2002 , 6, 121-30; discussion 130-4	1
945	Pharmacological Treatment of Dementia: A Review. 2002 , 199-271	3
944	Astrocytosis, microgliosis, metallothionein-I-II and amyloid expression in high cholesterol-fed rabbits. 2002 , 4, 1-9	34
943	Implications of amyloid precursor protein and subsequent beta-amyloid production to the pharmacotherapy of Alzheimer's disease. 2002 , 22, 1547-63	8

942	24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. 2002 , 36, 27-32	199
941	Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins. 2002 , 958, 100-11	34
940	Cholesterol, oxidative stress, and Alzheimer's disease: expanding the horizons of pathogenesis. 2002 , 33, 173-81	62
939	Association between high-density lipoprotein and cognitive impairment in the oldest old. 2002 , 51, 716-21	143
938	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial. 2002 , 52, 346-50	304
937	Alpha1-antichymotrypsin/Alzheimer's peptide Abeta(1-42) complex perturbs lipid metabolism and activates transcription factors PPARgamma and NFkappaB in human neuroblastoma (Kelly) cells. 2002 , 67, 511-22	22
936	Mevastatin induces degeneration and decreases viability of cAMP-induced differentiated neuroblastoma cells in culture by inhibiting proteasome activity, and mevalonic acid lactone prevents these effects. 2002 , 68, 627-35	29
935	Amyloid beta-protein affects cholesterol metabolism in cultured neurons: implications for pivotal role of cholesterol in the amyloid cascade. 2002 , 70, 438-46	50
934	Cholesterol and pathological processes in Alzheimer's disease. 2002 , 70, 361-6	62
933	Targeting APP metabolism for the treatment of Alzheimer's disease. 2002 , 56, 211-227	13
932	Statin therapy for Alzheimer's disease: will it work?. 2002 , 19, 155-61	140
931	Glioma cell activation by Alzheimer's peptide Abeta1-42, alpha1-antichymotrypsin, and their mixture. 2002 , 59, 1734-43	12
930	Statins: the new aspirin?. 2002 , 59, 1771-86	72
929	The biological role of the Alzheimer amyloid precursor protein in epithelial cells. 2002 , 117, 171-80	56
928	In vitro fibrillogenesis of the amyloid beta 1-42 peptide: cholesterol potentiation and aspirin inhibition. 2002 , 33, 609-26	56
927	Glycolipid-enriched caveolae and caveolae-like domains in the nervous system. 1999 , 73, 1-11	94
926	The amyloid precursor protein interacts with neutral lipids. 2002 , 269, 2238-46	15
925	Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. 2002 , 7, 899-902	124

924	Therapeutic strategies for Alzheimer's disease. 2002 , 1, 859-66	144
923	Cholesterol in Alzheimer's disease and tauopathy. 2002 , 977, 367-75	97
922	Cholesterol-dependent aggregation of amyloid beta-protein. 2002 , 977, 384-6	36
921	The neurodegeneration mutant l4hrig interferes with cholesterol homeostasis and Appl processing. 2002 , 21, 6367-76	101
920	Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. 2002 , 1, 1-31	147
919	Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP). 2003 , 20, 233-9	70
918	The role of cholesterol in pathogenesis of Alzheimer's disease: dual metabolic interaction between amyloid beta-protein and cholesterol. 2003 , 27, 1-12	65
917	Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. 2003 , 28, 979-86	17
916	Inhibitory effects of <i>Bombus terrestris</i> Salicea on neuronal secretion of Alzheimer's beta-amyloid peptides, a neurodegenerative peptide. 2003 , 28, 1785-92	1
915	Beta-amyloid and cholinergic neurons. 2003 , 28, 499-506	23
914	[Magnetic resonance imaging in clinical diagnosis of dementia]. 2003 , 43, 513-20	2
913	Brain region-dependent increases in beta-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. 2003 , 110, 641-9	35
912	Treatment of Alzheimer's disease: current status and new perspectives. 2003 , 2, 539-47	590
911	The pharmacology of amyloid precursor protein processing. 2003 , 38, 145-57	42
910	Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. 2003 , 66, 2177-84	22
909	Statin effects on cholesterol micro-domains in brain plasma membranes. 2003 , 65, 843-56	147
908	Proteomic characterisation of neuronal sphingolipid-cholesterol microdomains: role in plasminogen activation. 2003 , 987, 107-16	36
907	Loss of nicotinic receptors induced by beta-amyloid peptides in PC12 cells: possible mechanism involving lipid peroxidation. 2003 , 71, 397-406	21

906	Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?. 2003 , 72, 141-6	96
905	Identity and function of gamma-secretase. 2003 , 74, 353-60	84
904	ADAMs family members as amyloid precursor protein alpha-secretases. 2003 , 74, 342-52	369
903	Association of the C766T polymorphism of the low-density lipoprotein receptor-related protein gene with Alzheimer's disease. 2003 , 121B, 128-30	31
902	Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. 2003 , 25, 72-8	230
901	Accumulation of flotillin-1 in tangle-bearing neurones of Alzheimer's disease. 2003 , 29, 451-61	38
900	Depletion of cellular cholesterol interferes with intracellular trafficking of liposome-encapsulated ovalbumin. 2003 , 81, 415-23	10
899	Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. 2003 , 84, 471-9	82
898	Alzheimer's disease: the pharmacological pathway. 2003 , 17, 419-28	40
897	[Cholesterol and statins in Alzheimer disease]. 2003 , 153, 258-9	2
896	Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease. 2003 , 17, 93-102	72
895	Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. 2003 , 4, 1190-6	105
894	Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. 2003 , 8, 635-8	55
893	Alzheimer's disease: the cholesterol connection. 2003 , 6, 345-51	668
892	The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. 2003 , 63, 139-52	38
891	Gamma-secretase activity is present in rafts but is not cholesterol-dependent. 2003 , 42, 13977-86	71
890	Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. 2003 , 160, 113-23	899
889	Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. 2003 , 163, 2155-64	109

888	Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. 2003 , 43, 545-84	717
887	Role of cholesterol in synapse formation and function. 2003 , 1610, 271-80	209
886	Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. 2003 , 1610, 281-90	124
885	Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. 2003 , 350, 161-4	42
884	Cholesterol deficiency increases the vulnerability of hippocampal glia in primary culture to glutamate-induced excitotoxicity. 2003 , 43, 197-209	27
883	Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. 2003 , 24, 147-55	67
882	ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. 2003 , 24, 421-6	131
881	Lovastatin enhances Abeta production and senile plaque deposition in female Tg2576 mice. 2003 , 24, 637-43	114
880	High cholesterol affects platelet APP processing in controls and in AD patients. 2003 , 24, 631-6	20
879	Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. 2003 , 110, 119-25	85
878	Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. 2003 , 43, 1-16	233
877	Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. 2003 , 35, 1505-35	152
876	Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts. 2003 , 60, 1200-8	82
875	Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. 2003 , 20, 399-418	26
874	Broad substrate specificity of human cytochrome P450 46A1 which initiates cholesterol degradation in the brain. 2003 , 42, 14284-92	104
873	Dynamics of membrane lipid domains in neuronal cells differentiated in culture. 2003 , 44, 2142-51	59
872	Vaccines for Alzheimer's disease: how close are we?. 2003 , 17, 457-74	35
871	Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. 2003 , 278, 38421-7	63

870	Cell surface orifices of caveolae and localization of caveolin to the necks of caveolae in adipocytes. 2003 , 14, 3967-76	111
869	Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. 2003 , 278, 22980-8	285
868	Molecular mechanisms of host-pathogen interaction: entry and survival of mycobacteria in macrophages. 2003 , 81, 45-96	18
867	Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. 2003 , 278, 51035-43	94
866	Expression of liver X receptor target genes decreases cellular amyloid beta peptide secretion. 2003 , 278, 27688-94	136
865	Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). 2003 , 278, 38829-39	291
864	Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease. 2003 , 44, 2019-29	62
863	Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. 2003 , 16, 25-30	87
862	Genetics, lifestyle and the roles of amyloid beta and oxidative stress in Alzheimer's disease. 2003 , 30, 639-67	33
861	Anti-Amyloidogenic Effect of <i>Allium sativum</i> in Alzheimer's Transgenic Model Tg2576. 2003 , 3, 95-107	24
860	Cholesterol distribution in the Golgi complex of DITNC1 astrocytes is differentially altered by fresh and aged amyloid beta-peptide-(1-42). 2003 , 278, 17150-7	24
859	22R-hydroxycholesterol and 9-cis-retinoic acid induce ATP-binding cassette transporter A1 expression and cholesterol efflux in brain cells and decrease amyloid beta secretion. 2003 , 278, 13244-56	184
858	Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 11735-40	11.5 306
857	Identification of phospholipid scramblase 1 as a novel interacting molecule with beta -secretase (beta -site amyloid precursor protein (APP) cleaving enzyme (BACE)). 2003 , 278, 15239-45	43
856	Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. 2003 , 163, 1053-7	192
855	Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. 2003 , 23, 2055-62	220
854	Hypertension, hypertension-clustering factors and Alzheimer's disease. 2003 , 25, 675-80	88
853	A beta, aging, and Alzheimer's disease: a tale, models, and hypotheses. 2003 , 25, 581-9	24

852	Brain cholesterol, statins and Alzheimer's Disease. 2003 , 36 Suppl 2, S113-9	29
851	Cholesterol modulates amyloid beta-peptide's membrane interactions. 2003 , 36 Suppl 2, S136-43	31
850	Pharmakotherapie der Demenzen. 2003 , 30, 512-518	
849	Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. 2003 , 61, 199-205	255
848	[Pathomechanisms and hypothesis-guided therapeutic strategies for late-onset Alzheimer's disease]. 2003 , 71 Suppl 1, S16-26	4
847	24S-hydroxycholesterol: a marker of brain cholesterol metabolism. 2003 , 36 Suppl 2, S102-6	50
846	Cholesterol and Aβ aggregation. 2003 , 36 Suppl 2, S127-9	4
845	Cholesterol and tau protein—findings in Alzheimer's and Niemann Pick C's disease. 2003 , 36 Suppl 2, S120-6	34
844	Statins can inhibit proliferation of human breast cancer cells in vitro. 2003 , 111, 47-8	78
843	Cholesterol, a modulator of membrane-associated Aβ-fibrillogenesis. 2003 , 36 Suppl 2, S130-5	8
842	Cholesterol trafficking and amyloid beta peptides. 2003 , 36 Suppl 2, S144-8	5
841	Neurosteroids: Cerebrospinal fluid levels for Alzheimer's disease and vascular dementia diagnostics. 2003 , 88, 5199-206	76
840	Preventing dementia: why we should focus on health promotion now. 2003 , 15, 111-9	13
839	Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. 2003 , 60, 29-35	187
838	Relationships between plasma beta-amyloid peptide 1-42 and atherosclerotic risk factors in community-based older populations. 2003 , 49, 374-9	10
837	23 Antidementive Therapie. 2003 ,	
836	. 2003 ,	9
835	Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. 2003 , 23, 5645-9	156

834	Pharmacological Treatment of Dementia: A Review. 2003 , 199-278	1
833	Molecular Mechanisms of Neurodegenerative Disorders. 377-409	
832	Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. 2003 , 23, 3262-71	474
831	3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. 2003 , 23, 11104-11	206
830	. 2004 ,	2
829	Linking lipids, Alzheimer's and LXRs?. 2004 , 2, e001	8
828	ADAM proteases: protective role in Alzheimer's and prion diseases?. 2004 , 1, 165-74	17
827	Association between statin use and Alzheimer's disease. 2004 , 23, 94-8	162
826	Neurodegenerative disorders and cholesterol. 2004 , 1, 271-5	17
825	Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. 2004 , 3, 717-25	14
824	Modulation of amyloid precursor protein cleavage by cellular sphingolipids. 2004 , 279, 11984-91	68
823	A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. 2004 , 167, 809-12	66
822	Differential expression of cholesterol hydroxylases in Alzheimer's disease. 2004 , 279, 34674-81	196
821	Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. 2004 , 541, 135-52	127
820	Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. 2004 , 45, 186-93	230
819	Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of amyloid-beta peptide. 2004 , 18, 836-8	76
818	The role of cholesterol and statins in Alzheimer's disease. 2004 , 38, 91-8	54
817	SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 allele. 2004 , 18, 245-9	16

816	Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. 2004 , 78, 2682-92	87
815	Cholesterol is required for endocytosis and endosomal escape of adenovirus type 2. 2004 , 78, 3089-98	75
814	Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model. 2004 , 13, 1959-68	29
813	Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. 2004 , 279, 44945-54	341
812	Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. 2004 , 279, 48238-45	53
811	Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. 2004 , 26, 525-39	132
810	BACE1 and presenilin: two unusual aspartyl proteases involved in Alzheimer's disease. 2004 , 1, 168-74	21
809	Plasmin deficiency in Alzheimer's disease brains: causal or casual?. 2004 , 1, 205-12	20
808	Pleiotropic Effects of Statins. 2004 , 39, 239-258	2
807	Functions of lipoprotein receptors in neurons. 2004 , 45, 403-9	113
806	Neuronal membrane cholesterol loss enhances amyloid peptide generation. 2004 , 167, 953-60	271
805	Apolipoprotein E modulates gamma-secretase cleavage of the amyloid precursor protein. 2004 , 90, 1132-43	79
804	Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. 2004 , 66, 1-16	53
803	Increased iron staining in the cerebral cortex of cholesterol fed rabbits. 2004 , 125, 305-13	17
802	APP induces neuronal apoptosis through APP-BP1-mediated downregulation of beta-catenin. 2004 , 9, 415-22	22
801	Cholesterol efflux as a critical component of Alzheimer's disease pathogenesis. 2004 , 23, 219-24	33
800	Role of acyl-coenzyme a: cholesterol acyltransferase activity in the processing of the amyloid precursor protein. 2004 , 24, 93-6	29
799	Cholesterol, copper, and accumulation of thioflavine S-reactive Alzheimer's-like amyloid beta in rabbit brain. 2004 , 24, 97-104	24

798	Amyloid precursor protein compartmentalization restricts beta-amyloid production: therapeutic targets based on BACE compartmentalization. 2004 , 24, 137-43		35
797	Links between the pathology of Alzheimer's disease and vascular dementia. 2004 , 29, 1257-66		80
796	Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain. 2004 , 29, 1897-911		61
795	Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage?. 2004 , 1012, 51-64		71
794	Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. 2004 , 10, 229-48		231
793	Interactions of Alzheimer amyloid peptides with cultured cells and brain tissue, and their biological consequences. 2004 , 76, 4-14		16
792	Ginkgo biloba extract (Egb 761) inhibits beta-amyloid production by lowering free cholesterol levels. 2004 , 15, 749-56		80
791	Metabolite-initiated protein misfolding may trigger Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004 , 101, 4752-7	11.5	195
790	Obesity-related leptin regulates Alzheimer's Aβ. 2004 , 18, 1870-8		241
789	Purification and characterization of the human gamma-secretase complex. 2004 , 43, 9774-89		206
788	Effect of serum cholesterol on the mRNA content of amyloid precursor protein in rat livers. 2004 , 150, 157-66		2
787	Segregation of Nogo66 receptors into lipid rafts in rat brain and inhibition of Nogo66 signaling by cholesterol depletion. 2004 , 577, 87-92		27
786	Gene expression profiling of scrapie-infected brain tissue. 2004 , 323, 556-64		98
785	High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs. 2004 , 69, 431-8		99
784	Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer's disease. 2004 , 25, 1305-8		12
783	Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. 2004 , 164, 757-61		118
782	Intracellular accumulation of amyloidogenic fragments of amyloid-beta precursor protein in neurons with Niemann-Pick type C defects is associated with endosomal abnormalities. 2004 , 164, 975-85		177
781	ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. 2004 , 165, 1413-22		50

780	Exclusion of CYP46 and APOM as candidate genes for Alzheimer's disease in a French population. 2004 , 363, 139-43	37
779	Effects of high cholesterol diet on gliosis in apolipoprotein E knockout mice. Implications for Alzheimer's disease and stroke. 2004 , 369, 87-92	39
778	Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease. 2004 , 367, 228-31	34
777	Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese. 2004 , 369, 104-7	36
776	Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. 2004 , 368, 303-8	102
775	Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. 2004 , 371, 209-14	27
774	Increased caveolin-1 expression in Alzheimer's disease brain. 2004 , 25, 753-9	99
773	Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease. 2004 , 25, 977-89	81
772	Two types of Alzheimer's beta-amyloid (1-40) peptide membrane interactions: aggregation preventing transmembrane anchoring versus accelerated surface fibril formation. 2004 , 335, 1039-49	327
771	Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. 2004 , 363, 1139-46	431
770	Association of dyslipidemia and effects of statins on nonmacrovascular diseases. 2004 , 26, 337-51	17
769	Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. 2004 , 61, 333-7	94
768	Advances on biological markers in early diagnosis of Alzheimer disease. 2005 , 39, 107-29	2
767	Statins and cognition: what can we learn from existing randomized trials?. 2005 , 10, 867-74	21
766	From Intramolecular Asymmetries to Raft Assemblies. 2005 , 1-14	4
765	The Amyloid β Protein. 384-491	2
764	Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. 2005 , 92, 1386-98	165
763	Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. 2005 , 7, 1118-23	337

762	Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. 2005 , 11, 545-50	254
761	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. 2005 , 86, 173-85	41
760	Cholesterol in Alzheimer's disease. 2005 , 4, 841-52	251
759	Oligomerization of amyloid beta-protein occurs during the isolation of lipid rafts. 2005 , 80, 114-9	24
758	Lovastatin stimulates up-regulation of alpha7 nicotinic receptors in cultured neurons without cholesterol dependency, a mechanism involving production of the alpha-form of secreted amyloid precursor protein. 2005 , 82, 531-41	20
757	[Statins for treatment of CNS diseases. Status report from research and clinical practice]. 2005 , 76, 426-37	4
756	Statin treatment and a disease-specific pattern of beta-amyloid peptides in Alzheimer's disease. 2005 , 164, 205-14	28
755	Alzheimer's associated inflammation, potential drug targets and future therapies. 2005 , 112, 429-53	82
754	Statins: drugs for Alzheimer's disease?. 2005 , 112, 1057-71	45
753	Alzheimer's disease--a dysfunction in cholesterol and lipid metabolism. 2005 , 25, 475-83	40
752	Neurodegeneration. 2005 , 335-355	
751	Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. 2005 , 62, 217-24	254
750	Cholesterol and amyloid beta fibrillogenesis. 2005 , 38, 179-202	19
749	Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. 2005 , 2, e18	111
748	Statins and cognitive function in the elderly: the Cardiovascular Health Study. 2005 , 65, 1388-94	126
747	Association of active gamma-secretase complex with lipid rafts. 2005 , 46, 904-12	111
746	Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. 2005 , 280, 36815-23	228
745	The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. 2005 , 280, 43243-56	176

744	High total cholesterol levels in late life associated with a reduced risk of dementia. 2005 , 64, 1689-95		281
743	Raft lipids as common components of human extracellular amyloid fibrils. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 6297-302	11.5	174
742	3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate beta-amyloid-induced microglial inflammatory responses. 2005 , 25, 299-307		152
741	Alzheimer's Disease. 2005 ,		7
740	Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 18700-5	11.5	202
739	Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. 2005 , 280, 18755-70		108
738	Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. 2005 , 76, 1624-9		73
737	Cholesterol and apolipoprotein E in Alzheimer's disease. 2005 , 20, 91-6		35
736	Cholesterol-mediated neurite outgrowth is differently regulated between cortical and hippocampal neurons. 2005 , 280, 42759-65		65
735	The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. 2005 , 19, 256-65		65
734	Cholesterol and apoE: a target for Alzheimer's disease therapeutics. 2005 , 4, 553-67		6
733	Cholesterol-dependent lipid assemblies regulate the activity of the ecto-nucleotidase CD39. 2005 , 280, 26406-14		72
732	Mechanisms of statin-mediated inhibition of small G-protein function. 2005 , 280, 34202-9		179
731	Estatinas y enfermedad de Alzheimer: ¿son concluyentes los estudios actuales?. 2005 , 17, 2-6		
730	Cholesterol and Alzheimer's disease: statins, cholesterol depletion in APP processing and Abeta generation. 2005 , 38, 365-80		15
729	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. 2005 , 115, 1121-9		178
728	The link between cholesterol and Alzheimer's disease. 2005 , 6, 85-97		34
727	ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. 2005 , 18, 119-25		84

726	Association between acyl-coenzyme A: cholesterol acyltransferase gene and risk for Alzheimer's disease in Chinese. 2005 , 388, 17-20	14
725	Cholesterol depletion inhibits the degradation of amyloid beta-peptide in rat pheochromocytoma (PC12) cells. 2005 , 391, 71-5	8
724	Amyloid beta peptide-induced cholinergic fibres loss in the cerebral cortex of the rat is modified by diet high in lipids and by age. 2005 , 29, 31-48	18
723	Tau phosphorylation: physiological and pathological consequences. 2005 , 1739, 280-97	289
722	The influence of phospholipid membranes on bovine calcitonin peptide's secondary structure and induced neurotoxic effects. 2005 , 37, 1656-69	21
721	Cholesterol homeostasis in neurons and glial cells. 2005 , 16, 193-212	157
720	Statin therapy in the treatment of Alzheimer disease: what is the rationale?. 2005 , 118 Suppl 12A, 48-53	33
719	Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope. 2005 , 51, 1-17	211
718	Pathophysiology of Alzheimer's disease. 2005 , 15, 727-53, ix	52
717	Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. 2005 , 16, 181-212	68
716	Artefactual effects of lipid-based cell transfection reagents on AbetaPP processing and Abeta production. 2006 , 13, 86-92	1
715	Pharmacological strategies for the prevention of Alzheimer's disease. 2006 , 7, 1-10	63
714	Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. 2006 , 6, 683-93	20
713	Statin use and the risk of Alzheimer's disease: the MIRAGE study. 2006 , 2, 96-103	38
712	The involvement of lipid rafts in Alzheimer's disease. 2006 , 23, 111-22	161
711	Effects of lipids and aging on the neurotoxicity and neuronal loss caused by intracerebral injections of the amyloid-beta peptide in the rat. 2006 , 197, 41-55	20
710	Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. 2006 , 580, 5525-32	52
709	Circulating biomarkers of cognitive decline and dementia. 2006 , 364, 91-112	106

708	Sphingolipids in apoptosis, survival and regeneration in the nervous system. 2006 , 1758, 1995-2015	52
707	Cholesterol depletion induces autophagy. 2006 , 351, 246-52	95
706	Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. 2006 , 88, 473-83	87
705	Toward prevention of Alzheimers disease--potential nutraceutical strategies for suppressing the production of amyloid beta peptides. 2006 , 67, 682-97	28
704	Human apoB overexpression and a high-cholesterol diet differently modify the brain APP metabolism in the transgenic mouse model of atherosclerosis. 2006 , 49, 393-400	30
703	Influence of lysosomal acid lipase polymorphisms on chromosome 10 on the risk of Alzheimer's disease and cholesterol metabolism. 2006 , 402, 262-6	8
702	Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. 2006 , 80, 165-76	59
701	Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. 2006 , 27, 1632-43	82
700	Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. 2006 , 52, 15-31	257
699	[Epidemiology of Alzheimer disease and related disorders]. 2006 , 22, 288-96	27
698	Statins inhibit the dimerization of beta-secretase via both isoprenoid- and cholesterol-mediated mechanisms. 2006 , 399, 205-14	43
697	Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. 2006 , 10, 399-406	85
696	LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. 2006 , 65, 866-72	107
695	High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. 2006 , 46, 812-6	39
694	Predementia and Dementia Syndromes: Possible Role of Lipoprotein Metabolism. 2006 , 3, 235-245	
693	Lipid Rafts in Trafficking and Processing of Prion Protein and Amyloid Precursor Protein. 2006 , 205-231	
692	The effects of ABCA1 on cholesterol efflux and Abeta levels in vitro and in vivo. 2006 , 98, 792-800	91
691	Chronic exposure to U18666A is associated with oxidative stress in cultured murine cortical neurons. 2006 , 98, 1278-89	31

690	Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. 2006 , 98, 1032-45	56
689	Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. 2006 , 99, 438-49	104
688	The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. 2004 , 10, 127-46	33
687	Role of cholesterol in amyloid cascade: cholesterol-dependent modulation of tau phosphorylation and mitochondrial function. 2006 , 185, 21-6	20
686	Altered membrane fluidity and lipid raft composition in presenilin-deficient cells. 2006 , 185, 27-32	31
685	Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. 2006 , 185, 63-70	79
684	Statin therapy in Alzheimer's disease. 2006 , 185, 78-86	77
683	Effect of statins on beta-amyloid metabolism in humans: potential importance for the development of senile plaques in Alzheimer's disease. 2006 , 185, 87-92	11
682	The role of pleiotropic effects of statins in dementia. 2006 , 185, 115-8	12
681	Effects of sphingomyelin, cholesterol and zinc ions on the binding, insertion and aggregation of the amyloid Aβ(1-40) peptide in solid-supported lipid bilayers. 2006 , 273, 1389-402	50
680	Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. 2000 , 924, 81-90	109
679	Reelin, lipoprotein receptors and synaptic plasticity. 2006 , 7, 850-9	405
678	The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Aβ generation in vivo. 2006 , 25, 432-43	144
677	Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. 2006 , 11, 721-36	274
676	The role of gonadotropins in Alzheimer's disease: potential neurodegenerative mechanisms. 2006 , 29, 257-69	23
675	Prions: protein only or something more? Overview of potential prion cofactors. 2006 , 29, 195-214	24
674	Changes in cholesterol metabolism are associated with PS1 and PS2 gene regulation in SK-N-BE. 2006 , 30, 311-22	11
673	Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. 2006 , 8, 319-28	40

672	Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. 2006 , 1, 151-70	293
671	Guanosine effect on cholesterol efflux and apolipoprotein E expression in astrocytes. 2006 , 2, 637-49	14
670	Polymorphism in neuropeptide Y influences CSF cholesterol levels but is no major risk factor of Alzheimer's disease. 2006 , 113, 231-8	8
669	Quantitative trait loci in ABCA1 modify cerebrospinal fluid amyloid-beta 1-42 and plasma apolipoprotein levels. 2006 , 51, 171-179	10
668	Effect of pravastatin on plasma sterols and oxysterols in men. 2006 , 62, 9-14	27
667	Isoprenylated proteins. 2006 , 63, 255-67	242
666	[Direct neuronal effects of statins]. 2006 , 77, 289-90, 292-3	1
665	U18666A-mediated apoptosis in cultured murine cortical neurons: role of caspases, calpains and kinases. 2006 , 18, 1572-83	19
664	Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. 2006 , 545, 51-64	499
663	Pathogenic mechanisms in Alzheimer's disease. 2006 , 545, 29-38	34
662	Serum total cholesterol as a biomarker for Alzheimer's disease: mid-life or late-life determinations?. 2006 , 41, 805-6	13
661	Cholesterol deficiency perturbs actin signaling and glutamate homeostasis in hippocampal astrocytes. 2006 , 1104, 27-38	23
660	Lipid metabolism in cognitive decline and dementia. 2006 , 51, 275-92	132
659	Cholesterol and Alzheimer's disease--is there a relation?. 2006 , 127, 138-47	72
658	Isoprenoids and Alzheimer's disease: a complex relationship. 2006 , 22, 209-22	68
657	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. 2006 , 23, 573-7	66
656	Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer's disease mouse models with abundant A beta in plasma. 2006 , 24, 114-27	96
655	Amyloid beta oligomerization is induced by brain lipid rafts. 2006 , 99, 878-89	88

654	BACE1 interacts with lipid raft proteins. 2006 , 84, 912-7	74
653	Simvastatin enhances learning and memory independent of amyloid load in mice. 2006 , 60, 729-39	127
652	Polymorphism in ABCA1 influences CSF 24S-hydroxycholesterol levels but is not a major risk factor of Alzheimer's disease. 2006 , 17, 791	2
651	Role of amyloid precursor protein, amyloid-beta and gamma-secretase in cholesterol maintenance. 2006 , 3, 305-11	18
650	Therapeutic perspectives in Alzheimer's disease. 2006 , 1, 119-27	20
649	Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. 2006 , 66, 223-7	94
648	Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. 2006 , 12, 719-38	28
647	The role of the endoplasmic reticulum in the accumulation of beta-amyloid peptide in Alzheimer's disease. 2006 , 6, 119-33	32
646	Apolipoprotein E recycling: implications for dyslipidemia and atherosclerosis. 2006 , 26, 442-8	103
645	Lipids and the pathogenesis of Alzheimer's disease: is there a link?. 2006 , 18, 173-86	42
644	Modulation of the cellular cholesterol level affects shedding of the type XIII collagen ectodomain. 2006 , 281, 33352-62	10
643	The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration. 2007 , 78, 233-9	61
642	Hematologic risk factors of vascular disease and their relation to dementia. 2006 , 21, 335-52	17
641	Therapeutic approaches to Alzheimer's disease. 2006 , 129, 2840-55	257
640	Caveolin-1 upregulation in senescent neurons alters amyloid precursor protein processing. 2006 , 38, 126-33	43
639	Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. 2007 , 282, 2851-61	140
638	The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. 2007 , 27, 10895-905	44
637	Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. 2007 , 21, 2742-52	61

- 636 Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. **2007**, 7, 473-85 36
- 635 Nanoparticles for the Treatment of Alzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives. **2007**,
- 634 Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer's disease therapeutics. **2007**, 4, 179-84 62
- 633 The therapeutic potential of statins in neurological disorders. **2007**, 14, 103-12 55
- 632 Statin-like drugs for the treatment of brain cholesterol loss in Alzheimer's disease. **2007**, 2, 173-6 4
- 631 Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. **2007**, 282, 35722-32 102
- 630 Invited commentary: lipoproteins and dementia - is it the apolipoprotein A-I?. **2007**, 165, 993-7 13
- 629 Cyclodextrins inhibit replication of scrapie prion protein in cell culture. **2007**, 81, 11195-207 37
- 628 Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production. **2007**, 72, 141-51 30
- 627 Lipid Membrane Domains in Glycobiology. **2007**, 697-731
- 626 Optic neuritis and vaccination investigation: failure to consider significant sex differences and multiple vaccine combinations. **2007**, 64, 1673-4; discussion 1674-5 3
- 625 Less atherosclerosis and lower blood pressure for a meaningful life perspective with more brain. **2007**, 49, 389-400 89
- 624 The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. **2007**, 48, 1022-34 36
- 623 Optic Neuritis and Vaccination Investigation: Failure to Consider Significant Sex Differences and Multiple Vaccine CombinationsReply. **2007**, 64, 1674 1
- 622 Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. **2007**, 23, 194-201 67
- 621 Regulation of the lipidation of beta-secretase by statins. **2007**, 35, 577-82 14
- 620 Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. **2007**, 64, 1672-3 13
- 619 Cholesterol-lowering drugs and Alzheimer's disease. **2007**, 2, 423-432 13

618	Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. 2007 , 18, 325-32	46
617	Role of lipid rafts in the processing of the pathogenic prion and Alzheimer's amyloid-beta proteins. 2007 , 18, 638-48	43
616	Impact of HMG-CoA reductase inhibition on brain pathology. 2007 , 28, 342-9	52
615	Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. 2007 , 28, 8-17	85
614	Amyloid beta-protein and lipid metabolism. 2007 , 1768, 1991-2001	33
613	Formation of amyloids by Abeta-(1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. 2007 , 371, 924-33	66
612	The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. 2007 , 34, 621-8	193
611	Amyloid beta as a regulator of lipid homeostasis. 2007 , 13, 337-44	60
610	The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. 2007 , 416, 66-70	23
609	Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death. 2007 , 28, 613-21	21
608	Links Between Amyloid and Tau Biology in Alzheimer's Disease and Their Cholinergic Aspects. 2007 , 597-656	2
607	BACE1 expression and activity: relevance in Alzheimer's disease. 2007 , 4, 117-26	15
606	Abeta Peptide and Alzheimer's Disease. 2007 ,	1
605	Neuropsychiatric Disorders An Integrative Approach. 2007 ,	4
604	Exploring the Vertebrate Central Cholinergic Nervous System. 2007 ,	14
603	Statins reduce amyloid-beta production through inhibition of protein isoprenylation. 2007 , 282, 26832-26844	130
602	Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts. 2007 , 3, 374-82	72
601	Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. 2007 , 21, 449-62	36

600	Lipid rafts in health and disease. 2007 , 99, 129-40	224
599	Protein-protein interactions in the assembly and subcellular trafficking of the BACE (beta-site amyloid precursor protein-cleaving enzyme) complex of Alzheimer's disease. 2007 , 35, 974-9	16
598	Alzheimer's disease prevention – The emerging role of lipids and diet. 2007 , 14, 182-185	1
597	Changes in Cholesterol Metabolism in Peripheral Cells of Alzheimer Disease Patients and Their Relatives. 2007 ,	
596	Statins induce differentiation and cell death in neurons and astroglia. 2007 , 55, 1-12	60
595	Apolipoprotein E genotype and alpha-tocopherol modulate amyloid precursor protein metabolism and cell cycle regulation. 2007 , 51, 1510-7	8
594	Gas chromatographic-mass spectrometric determination of brain levels of alpha-cholest-8-en-3beta-ol (lathosterol). 2007 , 850, 177-82	11
593	ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. 2007 , 2, 14	56
592	Cholesterol-dependent balance between evoked and spontaneous synaptic vesicle recycling. 2007 , 579, 413-29	117
591	Cognitive dysfunction associated with metabolic syndrome. 2007 , 8, 409-18	61
590	Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. 2007 , 26, 882-9	37
589	Caveolin-1 and -2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. 2007 , 33, 317-27	23
588	Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer's disease. 2007 , 55, 133-5	13
587	24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. 2007 , 100, 968-78	47
586	Effects of human apolipoprotein E isoforms on the amyloid beta-protein concentration and lipid composition in brain low-density membrane domains. 2007 , 101, 949-58	6
585	Cholesterol independent effect of LXR agonist TO-901317 on gamma-secretase. 2007 , 101, 929-36	23
584	A specific inhibitor of cholesterol biosynthesis, BM15.766, reduces the expression of beta-secretase and the production of amyloid-beta in vitro. 2007 , 102, 1276-91	11
583	Oxysterols, cholesterol homeostasis, and Alzheimer disease. 2007 , 102, 1727-1737	131

582	Alzheimer's disease: the lipid connection. 2007 , 103 Suppl 1, 159-70	159
581	Altered cholesterol metabolism in APP695-transfected neuroblastoma cells. 2007 , 1152, 209-14	6
580	Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. 2007 , 11, 383-92	95
579	Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). 2007 , 28, 16-29	112
578	Neurodegeneration in autoimmune demyelination: recent mechanistic insights reveal novel therapeutic targets. 2007 , 184, 17-26	40
577	Cholesterol: nieuw therapeutisch target bij de ziekte van Alzheimer?. 2007 , 11, 64-68	
576	Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. 2007 , 35, 21-44	91
575	Alzheimer disease--no target for statin treatment. A mini review. 2007 , 32, 695-706	20
574	Alzheimer's disease and cholesterol: the fat connection. 2007 , 32, 739-50	65
573	Plasma 24S hydroxycholesterol response to statins in Alzheimer's disease patients: effects of gender, CYP46, and ApoE polymorphisms. 2007 , 33, 51-5	13
572	Complex of amyloid beta peptides with 24-hydroxycholesterol and its effect on hemicholinium-3 sensitive carriers. 2008 , 33, 412-21	21
571	Substrate specificity of gamma-secretase and other intramembrane proteases. 2008 , 65, 1311-34	229
570	How is protein aggregation in amyloidogenic diseases modulated by biological membranes?. 2008 , 37, 247-55	167
569	Disordered proteins: biological membranes as two-dimensional aggregation matrices. 2008 , 52, 175-89	42
568	Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to Abeta and insulin degradation. 2008 , 3, 22	31
567	Green tea catechins prevent cognitive deficits caused by Abeta1-40 in rats. 2008 , 19, 619-26	99
566	Pharmacogenomics in Alzheimer's disease. 2008 , 448, 213-357	72
565	Diseases of protein aggregation and the hunt for potential pharmacological agents. 2008 , 3, 165-92	30

564	LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. 2008 , 7, 943-50	17
563	Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. 2008 , 104, 1145-66	167
562	Gene expression profile of quinacrine-cured prion-infected mouse neuronal cells. 2008 , 105, 239-50	12
561	Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. 2008 , 105, 1536-49	30
560	High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. 2008 , 106, 475-85	257
559	ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. 2008 , 106, 793-804	108
558	Spatial memory formation induces recruitment of NMDA receptor and PSD-95 to synaptic lipid rafts. 2008 , 106, 1658-68	48
557	Docosahexaenoic acid disrupts in vitro amyloid beta(1-40) fibrillation and concomitantly inhibits amyloid levels in cerebral cortex of Alzheimer's disease model rats. 2008 , 107, 1634-46	69
556	Fatty acids, lipid metabolism and Alzheimer pathology. 2008 , 585, 176-96	71
555	Seladin-1/DHCR24 protects neuroblastoma cells against Abeta toxicity by increasing membrane cholesterol content. 2008 , 12, 1990-2002	52
554	Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. 2008 , 29, 422-37	194
553	Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. 2008 , 32, 426-32	62
552	Structural studies of the transmembrane C-terminal domain of the amyloid precursor protein (APP): does APP function as a cholesterol sensor?. 2008 , 47, 9428-46	137
551	Neurodegenerative Diseases. 2008 , 565-588	0
550	Dynamics and Cleavability at the alpha-cleavage site of APP(684-726) in different lipid environments. 2008 , 95, 1460-73	12
549	Advances in Alzheimer's and Parkinson's Disease. 2008 ,	
548	Pharmacogenomics in drug discovery and development. Preface. 2008 , 448, v-vii	5
547	Palmitoylation of the C-terminal fragment of p75(NTR) regulates death signaling and is required for subsequent cleavage by gamma-secretase. 2008 , 37, 346-58	55

546	Cardiovascular risk factors and dementia. 2008 , 6, 100-18	138
545	Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. 2008 , 40, 181-98	198
544	Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. 2008 , 90, 426-36	85
543	Recycling of apolipoprotein E is not associated with cholesterol efflux in neuronal cells. 2008 , 1781, 232-8	17
542	Impact of cholesterol level upon APP and BACE proximity and APP cleavage. 2008 , 370, 207-12	49
541	The benefit of docosahexanoic acid on the migration of vascular smooth muscle cells is partially dependent on Notch regulation of MMP-2/-9. 2008 , 172, 1430-40	44
540	The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): design and baseline characteristics. 2008 , 4, 145-53	44
539	Effects of cardiovascular medications on rate of functional decline in Alzheimer disease. 2008 , 16, 883-92	84
538	Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD). 2008 , 13, 255-71	25
537	Perspectives of Alzheimer's disease treatments. 2008 , 89, 273-90	1
536	Independent inhibition of Alzheimer disease beta- and gamma-secretase cleavage by lowered cholesterol levels. 2008 , 283, 11302-11	82
535	Direct and potent regulation of gamma-secretase by its lipid microenvironment. 2008 , 283, 22529-40	201
534	ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. 2008 , 49, 1254-67	45
533	Cognitive performance and plasma levels of homocysteine, vitamin B12, folate and lipids in patients with Alzheimer disease. 2008 , 26, 384-90	26
532	Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. 2008 , 73, 1381-93	60
531	Identification of flotillin-2, a major protein on lipid rafts, as a novel target of p53 family members. 2008 , 6, 395-406	26
530	Docosahexaenoic acid and amyloid-beta peptide signaling in Alzheimer's disease. 2009 , 99, 55-70	11
529	Molecular genetics of Alzheimer's disease: an update. 2008 , 40, 562-83	175

528	Emerging and potential therapies for Alzheimer's disease. 2008 , 12, 693-704	26
527	Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. 2008 , 22, 47-54	48
526	Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. 2008 , 28, 2874-82	157
525	A fluorescent sphingolipid binding domain peptide probe interacts with sphingolipids and cholesterol-dependent raft domains. 2008 , 49, 1077-89	46
524	Cholesterol loss enhances TrkB signaling in hippocampal neurons aging in vitro. 2008 , 19, 2101-12	70
523	The cholesterol transport inhibitor U18666a regulates amyloid precursor protein metabolism and trafficking in N2aAPP "Swedish" cells. 2008 , 5, 448-56	16
522	Rabbits fed cholesterol-enriched diets exhibit pathological features of inclusion body myositis. 2008 , 294, R829-35	19
521	Functional role of lipoprotein receptors in Alzheimer's disease. 2008 , 5, 15-25	106
520	Lipids as key players in Alzheimer disease: alterations in metabolism and genetics. 2008 , 5, 4-14	14
519	Membrane microdomain switching: a regulatory mechanism of amyloid precursor protein processing. 2008 , 183, 339-52	55
518	Beyond Cholesterol: Statin Benefits in Alzheimer's Disease. 2007 , 53-80	1
517	HDL-replacement therapy: mechanism of action, types of agents and potential clinical indications. 2008 , 6, 1203-15	59
516	Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. 2008 , 15, 673-84	51
515	Cognitive Impairment and Diabetes. 2008 , 2, 218-223	
514	Cholesterol lowering and beyond: role of statins in Alzheimer's disease. 2008 , 4, 171-180	3
513	Vascular risk factors, cognitive decline, and dementia. 2008 , 4, 363-81	205
512	Statins in neurological disorders: mechanisms and therapeutic value. 2009 , 9, 1242-59	23
511	Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. 2009 , 284, 21899-21907	48

510	Alzheimer disease Abeta production in the absence of S-palmitoylation-dependent targeting of BACE1 to lipid rafts. 2009 , 284, 3793-803	119
509	Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. 2009 , 132, 1346-54	15
508	Variations in the effects on synthesis of amyloid beta protein in modulated autophagic conditions. 2009 , 31, 959-68	5
507	Plasmalogens in biological systems: their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. 2009 , 16, 2021-41	143
506	Modifiable Midlife Risk Factors for Late-Life Cognitive Impairment and Dementia. 2009 , 5, 73-92	82
505	Cholesterol Trafficking in the Brain. 2009 , 131-155	
504	Molecular insights into beta-galactoside alpha2,6-sialyltransferase secretion in vivo. 2009 , 19, 479-87	35
503	DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APP ^{swE} /PS1 ^{dE9} mice. 2009 , 33, 482-98	140
502	Membrane-targeted strategies for modulating APP and Abeta-mediated toxicity. 2009 , 13, 249-61	3
501	RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. 2009 , 13, 589-98	24
500	Neuronal death in Alzheimer's disease and therapeutic opportunities. 2009 , 13, 4329-48	71
499	Transcriptional profiles of receptors and transporters involved in brain cholesterol homeostasis at the blood-brain barrier: use of an in vitro model. 2009 , 1249, 34-42	66
498	Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Abeta42. 2009 , 57, 320-35	19
497	A survey of ABCA1 sequence variation confirms association with dementia. 2009 , 30, 1348-54	33
496	Cholesterol in the senile plaque: often mentioned, never seen. 2009 , 117, 31-4	11
495	Why lipids are important for Alzheimer disease?. 2009 , 326, 121-9	60
494	Age-dependent increase in desmosterol restores DRM formation and membrane-related functions in cholesterol-free DHCR24 ^{-/-} mice. 2009 , 34, 1167-82	7
493	Brain lipid composition in grey-lethal mutant mouse characterized by severe malignant osteopetrosis. 2009 , 26, 623-33	13

492	Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. 2009 , 37, 6-15	22
491	Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. 2009 , 14, 469-86	179
490	Cell biology, regulation and inhibition of beta-secretase (BACE-1). 2009 , 276, 1845-59	54
489	Haptoglobin binds apolipoprotein E and influences cholesterol esterification in the cerebrospinal fluid. 2009 , 110, 255-63	36
488	Broad DNA repair responses in neural injury are associated with activation of the IL-6 pathway in cholesterol-fed rabbits. 2009 , 111, 1011-21	23
487	Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. 2009 , 111, 1275-308	165
486	Analysis of neurosterols by GC-MS and LC-MS/MS. 2009 , 877, 2778-805	63
485	Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E. 2009 , 35, 239-48	85
484	The essential role of lipids in Alzheimer's disease. 2009 , 91, 804-9	49
483	Cyclodextrins promote protein aggregation posing risks for therapeutic applications. 2009 , 386, 526-31	26
482	Age-related influence of the HDL receptor SR-BI on synaptic plasticity and cognition. 2009 , 30, 407-19	22
481	Age-related accumulation of Reelin in amyloid-like deposits. 2009 , 30, 697-716	77
480	Higher total cholesterol, cognitive decline, and dementia. 2009 , 30, 546-8	15
479	Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes. 2009 , 162, 328-38	74
478	Lipoprotein receptors and cholesterol in APP trafficking and proteolytic processing, implications for Alzheimer's disease. 2009 , 20, 191-200	91
477	Lipids and membrane microdomains in HIV-1 replication. 2009 , 143, 162-76	131
476	Oxysterols and neurodegenerative diseases. 2009 , 30, 171-9	196
475	Cytotoxic effects of oxysterols associated with human diseases: Induction of cell death (apoptosis and/or oncosis), oxidative and inflammatory activities, and phospholipidosis. 2009 , 30, 153-70	206

474	Statins for the prevention of dementia. 2009 , CD003160	115
473	Cellular Lipid Metabolism. 2009 ,	4
472	Lipid management in the geriatric patient. 2009 , 38, 185-206	3
471	Neuroprotective effects of statins in an in vitro model of Alzheimer's disease. 2009 , 17, 503-17	19
470	Leptin: a novel therapeutic strategy for Alzheimer's disease. 2009 , 16, 731-40	103
469	Mild cholesterol depletion reduces amyloid-beta production by impairing APP trafficking to the cell surface. 2009 , 110, 220-30	49
468	Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. 2009 , 15, 358-74	113
467	Statins for the treatment of Alzheimer's disease and dementia. 2009 ,	1
466	Transcriptional effects of S100B on neuroblastoma cells: perturbation of cholesterol homeostasis and interference on the cell cycle. 2010 , 14, 345-59	12
465	Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. 2010 , 20 Suppl 1, S127-41	80
464	Lipids and cognition. 2010 , 20, 737-47	75
463	Caveolin-1 regulates β secretase-mediated APP processing by modulating spatial distribution of β secretase in membrane. 2010 , 22, 423-42	22
462	Changes in cognition and amyloid- β processing with long term cholesterol reduction using atorvastatin in aged dogs. 2010 , 22, 135-50	31
461	Chinese Herbal Medicine: Perspectives on Age-Related Neurodegenerative Diseases. 2010 , 143-170	
460	[Visualization of amyloid formation processes on cell membranes: gangliosides as key molecules for the onset of amyloidosis]. 2010 , 130, 1295-303	0
459	Non-amyloid Approaches To Alzheimer's Disease. 2010 , 405-446	
458	Dyslipidemia in the elderly: should it be treated?. 2010 , 33, 4-9	29
457	Chapter 24:Targeting ApoE in Alzheimer's Disease: Liver X Receptor Agonists as Potential Therapeutics. 2010 , 191-212	

456	Chapter 1: The Amyloid Hypothesis of Alzheimer's Disease and Prospects for Therapeutics. 2010 , 3-18	
455	Encephalopathies: the emerging diabetic complications. 2010 , 47, 279-93	135
454	Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders. 2010 , 41, 314-40	93
453	Membrane biophysics and mechanics in Alzheimer's disease. 2010 , 41, 138-48	40
452	Exploring new indications for statins beyond atherosclerosis: Successes and setbacks. 2010 , 55, 155-62	18
451	Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. 2010 , 11, 23	15
450	Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. 2010 , 1318, 167-77	38
449	Altered levels and distribution of amyloid precursor protein and its processing enzymes in Niemann-Pick type C1-deficient mouse brains. 2010 , 58, 1267-81	38
448	Regulation of cholesterol efflux by amyloid beta secretion. 2010 , 88, 1985-94	19
447	Increased expression of RXR α in dementia: an early harbinger for the cholesterol dyshomeostasis?. 2010 , 5, 36	20
446	Neurite-like structures induced by mevalonate pathway blockade are due to the stability of cell adhesion foci and are enhanced by the presence of APP. 2010 , 114, 832-42	5
445	Plasma membrane microdomains in aging and disease. 2010 , 10 Suppl 1, S41-52	47
444	Amyloid-Beta Peptide, Oxidative Stress and Inflammation in Alzheimer's Disease: Potential Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids. 2010 , 2010, 1-10	16
443	Cholesterol in Alzheimer's disease and other amyloidogenic disorders. 2010 , 51, 47-75	32
442	Ginkgo biloba extract in Alzheimer's disease: from action mechanisms to medical practice. 2010 , 11, 107-23	101
441	Oxysterols in biological systems: the gastrointestinal tract, liver, vascular wall and central nervous system. 2010 , 44, 47-73	33
440	In vivo composition of NMDA receptor signaling complexes differs between membrane subdomains and is modulated by PSD-95 and PSD-93. 2010 , 30, 8162-70	63
439	Secretory phospholipase A2 type III enhances alpha-secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. 2010 , 51, 957-66	27

438	Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. 2010 , 74, 956-64	309
437	Cholesterol reduction impairs exocytosis of synaptic vesicles. 2010 , 123, 595-605	126
436	The Role of Statins in the Prevention and Treatment of Alzheimer's Disease. 2010 , 26, 276-284	1
435	Cell density-dependent increase in the level of protease-resistant prion protein in prion-infected Neuro2a mouse neuroblastoma cells. 2010 , 91, 563-9	9
434	Diet and age interactions with regards to cholesterol regulation and brain pathogenesis. 2010 , 219683	22
433	Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. 2010 , 30, 6862-72	133
432	Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis. 2010 , 20, 1215-31	36
431	Amyloidosis and neurodegenerative diseases: current treatments and new pharmacological options. 2010 , 85, 1-17	21
430	Designed fluorescent probes reveal interactions between amyloid-beta(1-40) peptides and GM1 gangliosides in micelles and lipid vesicles. 2010 , 99, 1510-9	20
429	Dietary cholesterol modulates the excitability of rabbit hippocampal CA1 pyramidal neurons. 2010 , 479, 327-31	16
428	Lipid rafts: keys to neurodegeneration. 2010 , 82, 7-17	98
427	Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. 2010 , 1802, 406-15	46
426	Niemann-Pick type C cells show cholesterol dependent decrease of APP expression at the cell surface and its increased processing through the beta-secretase pathway. 2010 , 1802, 682-91	26
425	Alterations of cholesterol precursor levels in Alzheimer's disease. 2010 , 1801, 945-50	42
424	Intracellular cholesterol homeostasis and amyloid precursor protein processing. 2010 , 1801, 853-9	25
423	Membrane rafts in Alzheimer's disease beta-amyloid production. 2010 , 1801, 860-7	191
422	Cholesterol changes in Alzheimer's disease: methods of analysis and impact on the formation of enlarged endosomes. 2010 , 1801, 839-45	29
421	ACAT inhibition and amyloid beta reduction. 2010 , 1801, 960-5	45

420	Role of amyloid beta in lipid homeostasis. 2010 , 1801, 966-74		51
419	Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. 2010 , 1801, 846-52		58
418	Cholesterol accumulation in Niemann Pick type C (NPC) model cells causes a shift in APP localization to lipid rafts. 2010 , 393, 404-9		48
417	Involvement of AMP-activated-protein-kinase (AMPK) in neuronal amyloidogenesis. 2010 , 399, 487-91		61
416	Trafficking of amyloid β precursor protein products C83 and C99 on the endocytic pathway. 2010 , 401, 219-24		4
415	Dependency of β secretase complex activity on the structural integrity of the bilayer. 2010 , 402, 291-6		2
414	Serum sphingomyelins and ceramides are early predictors of memory impairment. 2010 , 31, 17-24		121
413	Higher incidence of mild cognitive impairment in familial hypercholesterolemia. 2010 , 123, 267-74		78
412	Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010 , 107, 1942-7	11.5	212
411	The 32-year relationship between cholesterol and dementia from midlife to late life. 2010 , 75, 1888-95		106
410	Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. 2010 , 77, 82-102		147
409	Cholesterol and statins in Alzheimer's disease: current controversies. 2010 , 223, 282-93		74
408	Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. 2010 , 210, 78-87		40
407	Higher serum total cholesterol levels in late middle age are associated with glucose hypometabolism in brain regions affected by Alzheimer's disease and normal aging. 2010 , 49, 169-76		50
406	Statins for the treatment of dementia. 2010 , CD007514		63
405	Synthesis of New Water-Soluble Cholesterol Derivatives. 2011 , 41, 2876-2887		2
404	Association of Alzheimer disease pathology with abnormal lipid metabolism: the Hisayama Study. 2011 , 77, 1068-75		73
403	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. 2011 , 15, 83-102		24

402	Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. 2011 , 63, 172-80	74
401	Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. 2011 , 76, 366-72	58
400	Alzheimer's disease: cholesterol a menace?. 2011 , 86, 1-12	27
399	Effects of fatty acid unsaturation numbers on membrane fluidity and β -secretase-dependent amyloid precursor protein processing. 2011 , 58, 321-9	128
398	Coenzyme Q10 and cognition in atorvastatin treated dogs. 2011 , 501, 92-5	14
397	The complex interplay of cardiovascular system and cognition: how to predict dementia in the elderly?. 2011 , 150, 123-9	31
396	Emerging roles for cholesterol in Huntington's disease. 2011 , 34, 474-86	85
395	A CYP46 T/C SNP modulates parahippocampal and hippocampal morphology in young subjects. 2011 , 32, 1023-32	5
394	Inhibition of fibroblast growth factor receptor 1 endocytosis promotes axonal branching of adult sensory neurons. 2011 , 188, 13-22	23
393	[Alzheimer's disease and vascular risk factors]. 2011 , 32 Suppl 1, S17-21	0
392	Atorvastatin and A β (1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease. 2011 , 228, 15-8	9
391	Fluorescent analysis of the cell-selective Alzheimer's disease α Peptide surface membrane binding: influence of membrane components. 2011 , 2011, 917629	6
390	Wild type and Tangier disease ABCA1 mutants modulate cellular amyloid- β production independent of cholesterol efflux activity. 2011 , 27, 441-52	8
389	Alzheimer's Disease as a Membrane-Associated Enzymopathy of β Amyloid Precursor Protein (APP) Secretases. 2011 , 177-194	2
388	Impacts of membrane biophysics in Alzheimer's disease: from amyloid precursor protein processing to α Peptide-induced membrane changes. 2011 , 2011, 134971	16
387	. 2011 ,	6
386	Mechanisms of amyloid-Beta Peptide uptake by neurons: the role of lipid rafts and lipid raft-associated proteins. 2010 , 2011, 548380	61
385	Omega-3 polyunsaturated fatty acids in the brain: metabolism and neuroprotection. 2011 , 16, 2653-70	59

384	Brain cholesterol in normal and pathological aging. 2011 , 18, 214-217	3
383	Lipid Rafts: Linking Alzheimer's Amyloid- β Production, Aggregation, and Toxicity at Neuronal Membranes. 2010 , 2011, 603052	118
382	The dynamics of CD147 in Alzheimer's disease development and pathology. 2011 , 26, 593-605	16
381	Endolysosome mechanisms associated with Alzheimer's disease-like pathology in rabbits ingesting cholesterol-enriched diet. 2010 , 22, 1289-303	31
380	Cholesterol and amyloid- β evidence for a cross-talk between astrocytes and neuronal cells. 2011 , 25, 645-53	28
379	Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease. 2011 , 116, 916-25	76
378	Induction of Alzheimer's-like changes in brain of mice expressing mutant APP fed excess methionine. 2011 , 116, 82-92	14
377	Cannabinoid receptor signalling in neurodegenerative diseases: a potential role for membrane fluidity disturbance. 2011 , 163, 1379-90	28
376	Fluorescent in situ visualization of sterols in Arabidopsis roots. 2011 , 6, 446-56	32
375	The α 7 nicotinic acetylcholine receptor function in hippocampal neurons is regulated by the lipid composition of the plasma membrane. 2011 , 589, 3163-74	32
374	Linking lipids to Alzheimer's disease: cholesterol and beyond. 2011 , 12, 284-96	596
373	Loss of amyloid precursor protein in a mouse model of Niemann-Pick type C disease exacerbates its phenotype and disrupts tau homeostasis. 2011 , 42, 349-59	16
372	β -sitosterol inhibits high cholesterol-induced platelet β -amyloid release. 2011 , 43, 691-7	25
371	Interactions of Npc1 and amyloid accumulation/deposition in the APP/PS1 mouse model of Alzheimer's. 2011 , 52, 213-8	17
370	Dietary lipids and their oxidized products in Alzheimer's disease. 2011 , 55 Suppl 2, S161-72	36
369	Oxysterols as biomarkers in neurodegenerative diseases. 2011 , 164, 515-24	149
368	Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. 2011 , 9, 651-61	14
367	Pharmacological Approaches of Alzheimer's Disease: An Update. 2011 , 6, 186-196	

366	Oxidative stress and cell membranes in the pathogenesis of Alzheimer's disease. 2011 , 26, 54-69	98
365	Structural insight into the differential effects of omega-3 and omega-6 fatty acids on the production of Aβ peptides and amyloid plaques. 2011 , 286, 6100-7	32
364	Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. 2011 , 68, 1239-44	155
363	Reliability and validity of food frequency questionnaire and nutrient biomarkers in elders with and without mild cognitive impairment. 2011 , 25, 49-57	35
362	Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms. 2011 , 286, 14028-39	144
361	Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. 2011 , 25, 1295-305	120
360	Association of low ejection fraction with impaired verbal memory in older patients with heart failure. 2011 , 68, 1021-6	57
359	Neuronal membranes are key to the pathogenesis of Alzheimer's disease: the role of both raft and non-raft membrane domains. 2011 , 8, 213-21	30
358	Palmitoylation targets AKAP79 protein to lipid rafts and promotes its regulation of calcium-sensitive adenylyl cyclase type 8. 2011 , 286, 32962-75	61
357	The effect of sodium metabisulfite on visual evoked potentials in rats with hypercholesterolemia. 2011 , 21, 479-86	2
356	Cholesterol-dependent energy transfer between fluorescent proteins-insights into protein proximity of APP and BACE1 in different membranes in Niemann-Pick type C disease cells. 2012 , 13, 15801-12	6
355	Generation of Alzheimer disease-associated amyloid A _{42/43} peptide by B-secretase can be inhibited directly by modulation of membrane thickness. 2012 , 287, 21326-34	74
354	Lipid rafts and Alzheimer's disease: protein-lipid interactions and perturbation of signaling. 2012 , 3, 189	112
353	Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease. 2012 , 209, 2501-13	106
352	Down-regulation of the ATP-binding cassette transporter 2 (Abca2) reduces amyloid-β production by altering Nicastrin maturation and intracellular localization. 2012 , 287, 1100-11	31
351	Lipids in Alzheimer's disease and their potential for therapy. 2012 , 7, 65-78	10
350	Cholesterol: its regulation and role in central nervous system disorders. 2012 , 2012, 292598	174
349	Alzheimer's disease, cerebrovascular disease, and the Aβ amyloid cascade. 2012 , 39, 712-28	128

348	Metabolic syndrome and cognitive decline among the oldest old in Okinawa: in search of a mechanism. The KOCHOA Project. 2012 , 67, 126-34	38
347	Lipids and adipokines as risk factors for Alzheimer's disease. 2012 , 29, 151-7	62
346	Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. 2012 , 30 Suppl 2, S127-45	41
345	Nutritional determinants of cognitive aging and dementia. 2012 , 71, 1-13	102
344	Regulation of cerebral cholesterol metabolism in Alzheimer disease. 2012 , 60, 576-82	26
343	Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. 2012 , 122, 409-19	6
342	Cholesterol metabolism is associated with soluble amyloid precursor protein production in Alzheimer's disease. 2012 , 123, 310-6	51
341	Cholesterol and Alzheimer's disease: a still poorly understood correlation. 2012 , 64, 931-5	28
340	Amyloid- β metabolism in Niemann-Pick C disease models and patients. 2012 , 27, 573-85	35
339	Amyloid beta (A β) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). 2012 ,	43
338	Reciprocal regulation of cholesterol and beta amyloid at the subcellular level in Alzheimer's disease. 2012 , 90, 753-64	15
337	Rafts, Nanoparticles and Neural Disease. 2012 , 2, 217-250	2
336	Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. 2012 , 5, 746-55	198
335	Implication of common and disease specific variants in CLU, CR1, and PICALM. 2012 , 33, 1846.e7-18	32
334	Role of ABC transporters in the pathogenesis of Alzheimer's disease. 2012 , 3, 820-31	94
333	Indinavir inhibits the expression of cytoplasmic aromatase and nuclear SREBP in the hippocampus of reperfusion injury-induced ischemic rats. 2012 , 130, 81-9	6
332	Cholesterol enhances amyloid β deposition in mouse retina by modulating the activities of A β -regulating enzymes in retinal pigment epithelial cells. 2012 , 424, 704-9	17
331	Abnormal cross-talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis. 2012 , 26, 3065-74	8

330	Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice. 2012 , 9, 197	81
329	Road to Alzheimer's disease: the pathomechanism underlying. 2012 , 79, 55-71	13
328	Upstream transcription factor 1 (USF1) polymorphisms associate with Alzheimer's disease-related neuropathological lesions: Tampere Autopsy Study. 2012 , 22, 765-75	12
327	Binding of β amyloid (1-42) peptide to negatively charged phospholipid membranes in the liquid-ordered state: modeling and experimental studies. 2012 , 103, 453-463	53
326	Trans fatty acids enhance amyloidogenic processing of the Alzheimer amyloid precursor protein (APP). 2012 , 23, 1214-23	57
325	Hypercholesterolemia accelerates intraneuronal accumulation of A β oligomers resulting in memory impairment in Alzheimer's disease model mice. 2012 , 91, 1169-76	51
324	Lipid metabolism and neuroinflammation in Alzheimer's disease: a role for liver X receptors. 2012 , 33, 715-46	53
323	Isoprenoids and related pharmacological interventions: potential application in Alzheimer's disease. 2012 , 46, 64-77	37
322	The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. 2012 , 336, 1168-71	351
321	Citrulline diet supplementation improves specific age-related raft changes in wild-type rodent hippocampus. 2013 , 35, 1589-606	10
320	The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. 2012 , 3, 8	53
319	A-Subclass ATP-Binding Cassette Proteins in Brain Lipid Homeostasis and Neurodegeneration. 2012 , 3, 17	32
318	ABC Transporters and the Alzheimer's Disease Enigma. 2012 , 3, 54	60
317	Parkin null cortical neuronal/glia cultures are resistant to amyloid- β 42 toxicity: a role for autophagy?. 2012 , 32, 57-76	11
316	Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics. 2012 , 2012, 518901	38
315	Cholesterol and synaptic compensatory mechanisms in Alzheimer's disease mice brain during aging. 2012 , 31, 813-26	23
314	Abstracts of VII Congresso Sindem, Italian Association for the study of Dementia linked to the Italian Neurological Society (SIN). March 22-24, 2012. Naples, Italy. 2012 , 29 Suppl 1, 5-109	28
313	Pharmacological actions of statins: a critical appraisal in the management of cancer. 2012 , 64, 102-46	303

- 312 The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. **2012**, 112, 5147-92 636
- 311 The role of APP proteolytic processing in lipid metabolism. **2012**, 217, 365-75 45
- 310 Dementia, stroke, and vascular risk factors; a review. **2012**, 7, 61-73 136
- 309 Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin. **2012**, 52, 167-202 217
- 308 MiR-106b impairs cholesterol efflux and increases A β levels by repressing ABCA1 expression. **2012**, 235, 476-83 140
- 307 Modulation of in vitro activity of zymogenic and mature recombinant human β -secretase by dietary plants. **2012**, 279, 1291-305 8
- 306 Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β -amyloid accumulation in adult mice. **2012**, 1262, 85-92 36
- 305 Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. **2012**, 133, 20-9 27
- 304 Cochrane review on 'Statins for the treatment of dementia'. **2013**, 28, 119-26 44
- 303 Statins reduce amyloid β -peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. **2013**, 38, 589-600 16
- 302 Competition between homodimerization and cholesterol binding to the C99 domain of the amyloid precursor protein. **2013**, 52, 5051-64 84
- 301 Molecular links between Alzheimer's disease and diabetes mellitus. **2013**, 250, 140-50 132
- 300 From evolution to revolution: miRNAs as pharmacological targets for modulating cholesterol efflux and reverse cholesterol transport. **2013**, 75, 60-72 36
- 299 Potential diagnostic applications of side chain oxysterols analysis in plasma and cerebrospinal fluid. **2013**, 86, 26-36 30
- 298 Substitution of membrane cholesterol with β -sitosterol promotes nonamyloidogenic cleavage of endogenous amyloid precursor protein. **2013**, 247, 227-33 24
- 297 Control of A β release from human neurons by differentiation status and RET signaling. **2013**, 34, 184-99 12
- 296 Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier. **2013**, 113, 1877-903 160
- 295 Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. **2013**, 86, 37-42 69

294	Soluble amyloid precursor protein- β rescues age-linked decline in neural progenitor cell proliferation. 2013 , 34, 2431-40	48
293	Dyslipidemia and the risk of Alzheimer's disease. 2013 , 15, 307	105
292	Role of cholesterol in APP metabolism and its significance in Alzheimer's disease pathogenesis. 2013 , 47, 37-63	92
291	Role for membrane remodeling in cell death: implication for health and disease. 2013 , 304, 141-57	50
290	Lipid-based signaling modulates DNA repair response and survival against Klebsiella pneumoniae infection in host cells and in mice. 2013 , 49, 798-807	14
289	Lipid raft disarrangement as a result of neuropathological progresses: a novel strategy for early diagnosis?. 2013 , 245, 26-39	37
288	Lipid rafts, synaptic transmission and plasticity: impact in age-related neurodegenerative diseases. 2013 , 64, 97-107	80
287	Overlapped metabolic and therapeutic links between Alzheimer and diabetes. 2013 , 47, 399-424	60
286	Links between copper and cholesterol in Alzheimer's disease. 2013 , 4, 111	29
285	Effect of Different Phospholipids on β Secretase Activity in the Non-Amyloidogenic Pathway of Alzheimer's Disease. 2013 , 14, 5879-98	30
284	Steroids as β Secretase modulators. 2013 , 27, 3775-85	32
283	Cholesterol homeostasis: a key to prevent or slow down neurodegeneration. 2012 , 3, 486	49
282	Smoking, hypercholesterolaemia and hypertension as risk factors for cognitive impairment in older adults. 2013 , 42, 306-11	32
281	Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. 2013 , 5, 608-25	70
280	The ABCA7 transporter, brain lipids and Alzheimer's disease. 2013 , 8, 97-108	1
279	Cross-talk of membrane lipids and Alzheimer-related proteins. 2013 , 8, 34	52
278	Pharmacological Treatment of Mild Cognitive Impairment as a Prodromal Syndrome of Alzheimer's Disease. 2013 , 11, 102-8	39
277	Hypercholesterolemia accelerates amyloid β induced cognitive deficits. 2013 , 31, 577-82	49

276	A review of the potential therapeutic role of statins in the treatment of Alzheimer's disease: current research and opinion. 2013 , 9, 55-63	10
275	Elevation in sphingomyelin synthase activity is associated with increases in amyloid-beta peptide generation. 2013 , 8, e74016	12
274	Alzheimer Disease and Metabolism: Role of Cholesterol and Membrane Fluidity. 2013 ,	0
273	Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. 2014 , 5, 47	20
272	Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. 2014 , 6, 71	34
271	Metals and cholesterol: two sides of the same coin in Alzheimer's disease pathology. 2014 , 6, 91	30
270	Lipids and Lipid Signaling in Drosophila Models of Neurodegenerative Diseases. 2014 , 327-336	2
269	Treatment of vascular risk factors in patients with a diagnosis of Alzheimer's disease: a systematic review. 2014 , 12, 160	40
268	Lipidomics of Alzheimer's disease. 2014 , 6, 541-61	36
267	Metabolomics in the Study of Alzheimer's Disease. 2014 , 64, 249-278	1
266	Effect of atorvastatin on memory in albino mice. 2014 , 8, HF01-4	3
265	Cholesterol balance in prion diseases and Alzheimer's disease. 2014 , 6, 4505-35	22
264	Cholesterol drives $\alpha(1-42)$ interaction with lipid rafts in model membranes. 2014 , 30, 13934-41	24
263	Cholesterol as a co-solvent and a ligand for membrane proteins. 2014 , 23, 1-22	91
262	Statins for the treatment of dementia. 2014 , CD007514	47
261	Simvastatin treatment preserves synaptic plasticity in APP ^{swe} /PS1 ^{dE9} mice. 2014 , 39, 315-29	18
260	Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. 2014 , 9, 60	55
259	Encephalopathies Accompanying Type 1 and Type 2 Diabetes. 2014 , 127-147	

258	Associations between serum cholesterol levels and cerebral amyloidosis. 2014 , 71, 195-200	148
257	The involvement of lipids in Alzheimer's disease. 2014 , 41, 261-74	43
256	Biogenesis and transport of membrane domains-potential implications in brain pathologies. 2014 , 96, 75-84	1
255	Atherosclerosis, biomarkers of atherosclerosis and Alzheimer's disease. 2014 , 124, 1-11	6
254	Studies in Diabetes. 2014 ,	1
253	Conformational changes induced by the A21G Flemish mutation in the amyloid precursor protein lead to increased A β production. 2014 , 22, 387-96	33
252	Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. 2014 , 10, S76-83	234
251	Mechanism of cholesterol-assisted oligomeric channel formation by a short Alzheimer β amyloid peptide. 2014 , 128, 186-95	68
250	MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. 2014 , 1841, 595-609	387
249	Hypercholesterolemia induces short-term spatial memory impairments in mice: up-regulation of acetylcholinesterase activity as an early and causal event?. 2014 , 121, 415-26	23
248	Amyloid precursor protein β and β -cleaved ectodomains exert opposing control of cholesterol homeostasis via SREBP2. 2014 , 28, 849-60	16
247	Mutations in Niemann Pick type C gene are risk factor for Alzheimer's disease. 2014 , 83, 559-62	15
246	Involvement of oxysterols in age-related diseases and ageing processes. 2014 , 18, 148-62	111
245	Preventing vascular effects on brain injury and cognition late in life: knowns and unknowns. 2014 , 24, 371-87	12
244	Benzofuran-chalcone hybrids as potential multifunctional agents against Alzheimer's disease: synthesis and in vivo studies with transgenic <i>Caenorhabditis elegans</i> . 2014 , 9, 2671-84	32
243	Increased susceptibility to amyloid- β -induced neurotoxicity in mice lacking the low-density lipoprotein receptor. 2014 , 41, 43-60	38
242	Lipid metabolism in Alzheimer's disease. 2014 , 30, 331-45	45
241	Dietary modulators of statin efficacy in cardiovascular disease and cognition. 2014 , 38, 1-53	9

240	ATP-binding cassette transporter A1: from metabolism to neurodegeneration. 2014 , 72 Pt A, 13-21	73
239	Biophysical alterations in lipid rafts from human cerebral cortex associate with increased BACE1/ABP interaction in early stages of Alzheimer's disease. 2015 , 43, 1185-98	40
238	Chronic cholesterol depletion by lovastatin suppresses MUC5AC gene expression in human airway epithelial cells. 2014 , 28, e125-9	5
237	Lovastatin Differentially Affects Neuronal Cholesterol and Amyloid- β Production in vivo and in vitro. 2015 , 21, 631-41	10
236	Arachidonic or Docosahexaenoic Acid Diet Prevents Memory Impairment in Tg2576 Mice. 2015 , 48, 149-62	25
235	Cholesterol Levels and Cognitive Impairments. 2015 , 743-751	2
234	ACAT1/SOAT1 as a therapeutic target for Alzheimer's disease. 2015 , 7, 2451-67	50
233	Phosphatidylethanolamine plasmalogen enhances the inhibiting effect of phosphatidylethanolamine on β secretase activity. 2015 , 157, 301-9	22
232	Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease. 2015 , 107, 75-81	101
231	Specific Binding of Cholesterol to the Amyloid Precursor Protein: Structure of the Complex and Driving Forces Characterized in Molecular Detail. 2015 , 6, 784-90	17
230	Localization and Trafficking of Amyloid- β Protein Precursor and Secretases: Impact on Alzheimer's Disease. 2015 , 45, 329-47	49
229	Cholesterol - A putative endogenous contributor towards Parkinson's disease. 2015 , 90, 125-33	43
228	How to Stabilize Both the Proteins and the Membranes: Diverse Effects of sHsps in Neuroprotection. 2015 , 527-562	3
227	Lipids in Amyloid- β Processing, Aggregation, and Toxicity. 2015 , 855, 67-94	37
226	Statins for Treating Alzheimer's Disease: Truly Ineffective?. 2015 , 73, 360-6	13
225	Arachidonic acid diet attenuates brain A β deposition in Tg2576 mice. 2015 , 1613, 92-9	27
224	Membrane lipid therapy: Modulation of the cell membrane composition and structure as a molecular base for drug discovery and new disease treatment. 2015 , 59, 38-53	121
223	Functional competition within a membrane: Lipid recognition vs. transmembrane helix oligomerization. 2015 , 1848, 1886-96	27

222	Inhibiting cholesterol degradation induces neuronal sclerosis and epileptic activity in mouse hippocampus. 2015 , 41, 1345-55	18
221	Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study. 2015 , 32, 743-54	9
220	APP overexpression in the absence of NPC1 exacerbates metabolism of amyloidogenic proteins of Alzheimer's disease. 2015 , 24, 7132-50	20
219	Interaction of NBD-labelled fatty amines with liquid-ordered membranes: a combined molecular dynamics simulation and fluorescence spectroscopy study. 2015 , 17, 27534-47	10
218	What can lipidomics tell us about the pathogenesis of Alzheimer disease?. 2015 , 396, 1281-91	14
217	Genetic obesity alters recruitment of TANK-binding kinase 1 and AKT into hypothalamic lipid rafts domains. 2015 , 80, 23-32	18
216	Changes in Membrane Cholesterol Differentially Influence Preferential and Non-preferential Signaling of the M1 and M3 Muscarinic Acetylcholine Receptors. 2015 , 40, 2068-77	12
215	Molecular Mechanism for Cellular Response to Æscin and Its Therapeutic Implications. 2016 , 11, e0164365	30
214	Tocotrienol Affects Oxidative Stress, Cholesterol Homeostasis and the Amyloidogenic Pathway in Neuroblastoma Cells: Consequences for Alzheimer's Disease. 2016 , 17,	29
213	The Rationale for Insulin Therapy in Alzheimer's Disease. 2016 , 21,	11
212	The Amyloid Precursor Protein of Alzheimer's Disease Clusters at the Organelle/Microtubule Interface on Organelles that Bind Microtubules in an ATP Dependent Manner. 2016 , 11, e0147808	4
211	ABCG1 and ABCG4 Suppress Æsecretase Activity and Amyloid ðProduction. 2016 , 11, e0155400	24
210	The Impact of Vitamin E and Other Fat-Soluble Vitamins on Alzheimer's Disease. 2016 , 17,	52
209	The Effects of Glycerophospholipids and Fatty Acids on APP Processing. 2016 , 377-421	1
208	Statins for the prevention of dementia. 2016 , CD003160	104
207	Relationship between plasma lipids and mild cognitive impairment in the elderly Chinese: a case-control study. 2016 , 15, 146	33
206	Alzheimer's Disease Risk Genes and Lipid Regulators. 2016 , 53, 15-29	39
205	Resistance Training, Lipid Profile, and Homocysteine in Patients with Alzheimer's Disease. 2016 , 10, 28-32	6

204	Phosphatidylcholine protects neurons from toxic effects of amyloid β protein in culture. 2016 , 1642, 376-383	18
203	Amyloid- β (1-42) Aggregation Initiates Its Cellular Uptake and Cytotoxicity. 2016 , 291, 19590-606	61
202	Carotenoids and Neurobiological Health. 2016 , 12, 199-228	13
201	Specific Binding of Cholesterol to C99 Domain of Amyloid Precursor Protein Depends Critically on Charge State of Protein. 2016 , 7, 3535-41	22
200	ABCA1-Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease. 2016 , 5,	41
199	Cerebral and blood correlates of reduced functional connectivity in mild cognitive impairment. 2016 , 221, 631-45	14
198	Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells. 2016 , 314, 47-63	31
197	The pleiotropic effects of omega-3 docosahexaenoic acid on the hallmarks of Alzheimer's disease. 2016 , 38, 1-11	63
196	Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice. 2016 , 74, 34-41	6
195	On the physiological/pathological link between A β peptide, cholesterol, calcium ions and membrane deformation: A molecular dynamics study. 2016 , 1858, 1380-9	11
194	The Amyloid β Precursor Protein and Cognitive Function in Alzheimer's Disease. 2016 , 97-133	2
193	Changes in astrocyte functional markers and β amyloid metabolism-related proteins in the early stages of hypercholesterolemia. 2016 , 316, 178-91	31
192	Amides of non-steroidal anti-inflammatory drugs with thiomorpholine can yield hypolipidemic agents with improved anti-inflammatory activity. 2016 , 26, 910-913	16
191	The dynamic binding of cholesterol to the multiple sites of C99: as revealed by coarse-grained and all-atom simulations. 2017 , 19, 3845-3856	9
190	Endogenous Brain Lipids Inhibit Prion Amyloid Formation. 2017 , 91,	19
189	Preliminary Results on Long-Term Potentiation-Like Cortical Plasticity and Cholinergic Dysfunction After Miglustat Treatment in Niemann-Pick Disease Type C. 2017 , 36, 19-27	15
188	Lipids as central modulators of sensory TRP channels. 2017 , 1859, 1615-1628	32
187	Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals. 2017 , 74, 718-726	87

186	Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. 2017 , 58, 2083-2101	50
185	The beneficial effects of HMG-CoA reductase inhibitors in the processes of neurodegeneration. 2017 , 32, 949-965	39
184	Alteration of high-density lipoprotein functionality in Alzheimer's disease patients. 2017 , 95, 894-903	12
183	Therapeutic Strategies in Neurodegenerative Diseases. 2017 , 681-711	
182	Molecular dynamics simulations of heterogeneous cell membranes in response to uniaxial membrane stretches at high loading rates. 2017 , 7, 8316	9
181	Sphingolipids: membrane microdomains in brain development, function and neurological diseases. 2017 , 7,	135
180	Effects of cholesterol transport inhibitor U18666A on APP metabolism in rat primary astrocytes. 2017 , 65, 1728-1743	10
179	Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid- β oligomers. 2017 , 474, 3045-3058	3
178	Solubilizing steroidal drugs by β -cyclodextrin derivatives. 2017 , 531, 559-567	28
177	JIMD Reports, Volume 36. 2017 ,	
176	Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease. 2017 , 123, 465-476	53
175	APP Function and Lipids: A Bidirectional Link. 2017 , 10, 63	54
174	Interplay of Energetics and ER Stress Exacerbates Alzheimer's Amyloid- β Toxicity in Yeast. 2017 , 10, 232	18
173	Elderly apolipoprotein E-/- mice with advanced atherosclerotic lesions in the aorta do not develop Alzheimer's disease-like pathologies. 2018 , 17, 2488-2492	3
172	Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: Mechanisms, contributors, and therapy. 2018 , 1860, 1876-1888	17
171	Systematic review of the efficacy of statins for the treatment of Alzheimer's disease. 2018 , 18, 54-61	19
170	Shedding Light on the Molecular Pathology of Amyloid Plaques in Transgenic Alzheimer's Disease Mice Using Multimodal MALDI Imaging Mass Spectrometry. 2018 , 9, 1802-1817	35
169	Recent studies on cellular and molecular mechanisms in Alzheimer's disease: focus on epigenetic factors and histone deacetylase. 2018 , 29, 241-260	19

168	Protection against the Neurotoxic Effects of β -Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of $\alpha 7$ Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. 2018 , 188, 1081-1093	5
167	Cholesterol ester hydrolase inhibitors reduce the production of synaptotoxic amyloid- β oligomers. 2018 , 1864, 649-659	6
166	Embedded in the Membrane: How Lipids Confer Activity and Specificity to Intramembrane Proteases. 2018 , 251, 369-378	8
165	Vitexin inhibits A β -induced toxicity in Neuro-2a cells by augmenting Nrf-2/HO-1 dependent antioxidant pathway and regulating lipid homeostasis by the activation of LXR- β 2018 , 50, 160-171	33
164	Endosomal-Lysosomal Cholesterol Sequestration by U18666A Differentially Regulates Amyloid Precursor Protein (APP) Metabolism in Normal and APP-Overexpressing Cells. 2018 , 38,	4
163	Amyloid and membrane complexity: The toxic interplay revealed by AFM. 2018 , 73, 82-94	24
162	Shared pathological pathways of Alzheimer's disease with specific comorbidities: current perspectives and interventions. 2018 , 144, 360-389	8
161	Calcium-Dependent Desensitization of NMDA Receptors. 2018 , 83, 1173-1183	23
160	Connecting the brain cholesterol and renin-angiotensin systems: potential role of statins and RAS-modifying medications in dementia. 2018 , 284, 620-642	19
159	Small molecule biomarkers in Alzheimer's disease. 2018 , 25, D404	5
158	Aging and Alzheimer's disease: Comparison and associations from molecular to system level. 2018 , 17, e12802	87
157	Amyloid- β (1-40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study. 2018 , 168, 855-865	15
156	Peptides as Potential Therapeutics for Alzheimer's Disease. 2018 , 23,	32
155	Lead exposure induces Alzheimer's disease (AD)-like pathology and disturbs cholesterol metabolism in the young rat brain. 2018 , 296, 173-183	25
154	Cholesterol catalyses A β 2 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. 2018 , 10, 673-683	126
153	Alzheimer's disease and the autophagic-lysosomal system. 2019 , 697, 49-58	28
152	Alzheimer's disease and type 2 diabetes mellitus are distinct diseases with potential overlapping metabolic dysfunction upstream of observed cognitive decline. 2019 , 29, 3-17	72
151	Lipid and Lipid Raft Alteration in Aging and Neurodegenerative Diseases: A Window for the Development of New Biomarkers. 2019 , 20,	58

150	Serum 24-hydroxycholesterol in probable Alzheimer's dementia: Reexploring the significance of a tentative Alzheimer's disease biomarker. 2019 , 2, 74-81	4
149	Neuroprotective and Antioxidant Effect of Ginkgo biloba Extract Against AD and Other Neurological Disorders. 2019 , 16, 666-674	88
148	Alzheimer's Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts. 2019 , 13, 309	61
147	Quercetin inhibition of SREBPs and ChREBP expression results in reduced cholesterol and fatty acid synthesis in C6 glioma cells. 2019 , 117, 105618	12
146	. 2019 ,	0
145	Molecular dynamics simulation of cell membrane pore sealing. 2019 , 27, 83-93	6
144	Ageing as a risk factor for neurodegenerative disease. 2019 , 15, 565-581	634
143	Association between selected cholesterol-related gene polymorphisms and Alzheimer's disease in a Turkish cohort. 2019 , 46, 1701-1707	4
142	Bioactive Lipids in Health and Disease. 2019 ,	2
141	Bioactive Lipids and the Gut-Brain Axis: Diet as a Modulator of Bioactivity and Diversity of Lipids in the Brain. 2019 , 1127, 147-168	1
140	Prevention and Treatment of Alzheimer's Disease: Biological Mechanisms of Exercise. 2019 , 69, 311-338	24
139	Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease. 2019 , 189-231	1
138	Association study of rs3846662 with Alzheimer's disease in a population-based cohort: the Cache County Study. 2019 , 84, 242.e1-242.e6	3
137	Elevated cellular cholesterol in Familial Alzheimer's presenilin 1 mutation is associated with lipid raft localization of β Amyloid precursor protein. 2019 , 14, e0210535	23
136	Cognition and Health Ageing. 2019 , 169-180	1
135	Profiling of Alzheimer's disease related genes in mild to moderate vitamin D hypovitaminosis. 2019 , 67, 123-137	7
134	Elevated Membrane Cholesterol Disrupts Lysosomal Degradation to Induce β Amyloid Accumulation: The Potential Mechanism Underlying Augmentation of β Amyloid Pathology by Type 2 Diabetes Mellitus. 2019 , 189, 391-404	2
133	Prostaglandin A1 Inhibits the Cognitive Decline of APP/PS1 Transgenic Mice via PPAR γ /ABCA1-dependent Cholesterol Efflux Mechanisms. 2019 , 16, 505-522	5

132	The amyloid precursor protein (APP) processing as a biological link between Alzheimer's disease and cancer. 2019 , 49, 83-91	25
131	The relationship between cholesterol level and Alzheimer's disease-associated APP proteolysis/A β metabolism. 2019 , 22, 453-463	17
130	Superpixel guided structure sparsity for multispectral and hyperspectral image fusion over couple dictionary. 2020 , 79, 4949-4964	9
129	Enhanced activity of superoxide dismutase is a common response to dietary and genetically induced increased cholesterol levels. 2020 , 23, 398-410	3
128	Amyloid- β -Independent regulators of tau pathology in Alzheimer disease. 2020 , 21, 21-35	176
127	The silence of the fats: A MAM's story about Alzheimer. 2020 , 145, 105062	4
126	Sigma-2 Receptor-A Potential Target for Cancer/Alzheimer's Disease Treatment via Its Regulation of Cholesterol Homeostasis. 2020 , 25,	7
125	MAM and C99, key players in the pathogenesis of Alzheimer's disease. 2020 , 154, 235-278	5
124	Clusterin as a Potential Biomarker of Obesity-Related Alzheimer's Disease Risk. 2020 , 15, 1177271920964108	1
123	Plasma High Density Lipoprotein Small Subclass is Reduced in Alzheimer's Disease Patients and Correlates with Cognitive Performance. 2020 , 77, 733-744	3
122	New Insights Into Targeting Membrane Lipids for Cancer Therapy. 2020 , 8, 571237	23
121	Redox signaling and Alzheimer's disease: from pathomechanism insights to biomarker discovery and therapy strategy. 2020 , 8, 42	8
120	Impact of Cholesterol Concentration and Lipid Phase on Structure and Fluctuation of Amyloid Precursor Protein. 2020 , 124, 10173-10185	2
119	Pleiotropic effects of statins on brain cells. 2020 , 1862, 183340	15
118	Bicelles Rich in both Sphingolipids and Cholesterol and Their Use in Studies of Membrane Proteins. 2020 , 142, 12715-12729	10
117	Revisiting the role of brain and peripheral A β in the pathogenesis of Alzheimer's disease. 2020 , 416, 116974	34
116	Prevention of multiple system atrophy using human bone marrow-derived mesenchymal stem cells by reducing polyamine and cholesterol-induced neural damages. 2020 , 11, 63	
115	The relationship between blood lipids and plasma amyloid beta is depend on blood pressure: a population-based cross-sectional study. 2020 , 19, 8	3

114	Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury. 2020 , 12, 33	5
113	A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy. 2021 , 41, 2689-2745	3
112	Acute exercise increases circulating IGF-1 in Alzheimer's disease patients, but not in older adults without dementia. 2021 , 396, 112903	2
111	Cholesterol-lowering drugs reduce APP processing to A β by inducing APP dimerization. 2021 , 32, 247-259	12
110	Association Between Gout and Dementia in the Elderly: A Nationwide Population-Based Cohort Study. 2021 , 29, 1177-1185	3
109	Cholesterol-containing lipid nanodiscs promote an β -synuclein binding mode that accelerates oligomerization. 2021 , 288, 1887-1905	7
108	The C99 domain of the amyloid precursor protein resides in the disordered membrane phase. 2021 , 296, 100652	2
107	Ginkgo biloba. 2021 , 199-215	
106	Structural and mechanistic insights into the inhibition of amyloid- β aggregation by A β fragment derived synthetic peptides. 2021 , 212, 113126	4
105	Phytosterols: Targeting Neuroinflammation in Neurodegeneration. 2021 , 27, 383-401	15
104	An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer's Disease. 2021 , 10,	4
103	Endosomal-lysosomal dysfunctions in Alzheimer's disease: Pathogenesis and therapeutic interventions. 2021 , 36, 1087-1100	3
102	Cholesterol and Alzheimer's Disease; From Risk Genes to Pathological Effects. 2021 , 13, 690372	21
101	Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial. 2021 ,	3
100	Altered insulin pathway compromises mitochondrial function and quality control both in in vitro and in vivo model systems. 2021 , 60, 178-188	3
99	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. 2021 , 71, 101451	4
98	Astrocytes deliver CK1 to neurons via extracellular vesicles in response to inflammation promoting the translation and amyloidogenic processing of APP. 2020 , 10, e12035	9
97	Kognitive Störungen: Koma, Delir, Demenz. 2006 , 221-295	6

96	Cholesterol: A Janus-Faced Molecule in the Central Nervous System. 2007 , 151-170	2
95	Cholesterol and Hydroxycholesterol in the Brain. 2011 , 267-297	1
94	Neuroprotective strategies in Alzheimer's disease. 2002 , 513, 475-96	6
93	Dietary Fatty Acids and Cognitive Function. 2002 , 31-46	2
92	Cholesterol and Alzheimer's Disease. 2007 , 142-158	1
91	Serum lipoprotein profile and APOE genotype in Alzheimer's disease. 2007 , 175-9	6
90	Ursachen und Behandlungskonzepte der Demenzen. 2001 , 113-199	2
89	Epidemiologie der Demenzen. 1999 , 9-32	13
88	Vascular Risk Factors for Alzheimer's Disease. 2000 , 43-58	1
87	Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. 2007 , 35, 21	2
86	Amyloid β peptide 1-40 increases neuronal membrane fluidity: role of cholesterol and brain region. 2001 , 42, 1292-1297	75
85	Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer's disease. 2000 , 41, 963-974	109
84	Dimerization and Structural Stability of Amyloid Precursor Proteins Affected by the Membrane Microenvironments. 2017 , 57, 1375-1387	17
83	Live-cell monitoring of protein localization to membrane rafts using protein-fragment complementation. 2020 , 40,	3
82	Cholesterol is a strong promotor of an β synuclein membrane binding mode that accelerates oligomerization.	5
81	Targeting the role of the endosome in the pathophysiology of Alzheimer's disease: a strategy for treatment. 2006 , 2006, re2	30
80	LRP: a multifunctional scavenger and signaling receptor. 2001 , 108, 779-84	387
79	Alzheimer disease therapy: Can the amyloid cascade be halted?. 2003 , 111, 11-18	116

78	Proteolytic processing and cell biological functions of the amyloid precursor protein. 2000 , 113, 1857-1870	418
77	Recent neuroimaging, neurophysiological, and neuropathological advances for the understanding of NPC. 2018 , 7, 194	9
76	LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease. 2010 , 5, e8556	27
75	Overexpression of the IGF-II/M6P receptor in mouse fibroblast cell lines differentially alters expression profiles of genes involved in Alzheimer's disease-related pathology. 2014 , 9, e98057	3
74	ApoE4-Induced Cholesterol Dysregulation and Its Brain Cell Type-Specific Implications in the Pathogenesis of Alzheimer's Disease. 2019 , 42, 739-746	21
73	Decreased serum lipids in patients with probable Alzheimer's disease. 2009 , 9, 215-20	26
72	Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. 2016 , 7, 13319-27	3
71	Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese. 2016 , 7, 22746-51	9
70	Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer's Disease. 2020 , 19, 85-93	20
69	[Dementia and dyslipidemia]. 2011 , 48, 114-7	1
68	Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease. 2018 , 1,	2
67	Is the distinction between Alzheimer's disease and vascular dementia possible and relevant?. 2003 , 5, 7-15	10
66	Neuroprotective effects of statins against amyloid β -induced neurotoxicity. 2018 , 13, 198-206	21
65	Experimental Analysis of Interacting HT22 Plasma Membrane Cholesterol and β Amyloid. 2017 , 06, 75-96	2
64	High Fibre Diets and Alzheimer's Disease. 2014 , 05, 410-424	12
63	Membrane Cholesterol Is a Critical Determinant for Hippocampal Neuronal Polarity. 2021 , 14, 746211	0
62	Genetic Basis of Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases. 2000 , 121-131	
61	Amyloidogenesis and Cholesterol. 2002 , 13-18	

- 60 Alzheimer's Disease: Search for Therapeutics. **2003**, 743-777 1
- 59 Linking Alzheimer's Disease, B-Amyloid, and Lipids. **2004**,
- 58 Assays for Analysis of APP Secretion and Recycling. **2004**,
- 57 β Amyloid Therapeutic Strategies for Alzheimer's Disease. 0
- 56 Statins and Toxicity. **2006**, 273-295
- 55 Beta Secretase. **2007**, 1-8
- 54 Increase of Amyloid-Beta Peptide Generation in High Cholesterol Diet Rabbit Brain. **2007**, 15, 34-39
- 53 Hybrid antioxidants. **2008**, 2, 163-171 2
- 52 Vascular Development, Stroke and Neurodegenerative Disease: A Place for Novel Clinical Interventions?. **2010**, 313-338
- 51 The Search for Biomarkers in Alzheimer's Disease. **2010**, 2, 4
- 50 Alzheimer's Disease: Risk Factors and Preventive Strategies. **2010**, 271-280
- 49 Thinking Outside the Box in Alzheimer Disease Treatment.
- 48 Alzheimer-Demenz und weitere neurodegenerative Erkrankungen. **2012**, 267-279
- 47 The Amyloid β -Protein and Alzheimer's Disease. **2012**, 1-85
- 46 Die Zukunft der Prävention und Therapie - Ein Ausblick. **1999**, 231-233
- 45 3. The role of cholesterol in disorders of brain and behavior: human and animal perspectives. **2016**, 53-70
- 44 5Chapter Role of Micronutrients in the Prevention of Coronary Artery Disease and Improvement of the Standard Therapy. **2016**, 81-102
- 43 PRFF Peptide Mimic Interferes with Toxic Fibrin-A β Interaction by Emulating the A β Binding Interface on Fibrinogen. **2021**, 12, 4144-4152 1

42	APP palmitoylation is involved in the increase in A β induced by aluminum. 2022 , 1774, 147709	0
41	Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. 2021 , 13, 766587	2
40	APP Biology, Processing and Function. 17-34	2
39	Cholesterol and A β Production: Methods for Analysis of Altered Cholesterol De Novo Synthesis. 2008 , 221-230	
38	Alzheimer disease therapy: can the amyloid cascade be halted?. 2003 , 111, 11-8	42
37	Neurobiologie psychischer Störungen. 2008 , 233-340	
36	Profiling of circulating chromosome 21-encoded microRNAs, miR-155 and Let-7c, in Down Syndrome People.	
35	Nutrient signaling pathways regulate amyloid clearance and synaptic loss in Alzheimer's disease.	
34	Mutations in the juxtamembrane segment of the cholesterol-binding site of APP alter its processing and promotes production of shorter, less toxic A β peptides.	
33	The C99 domain of the amyloid precursor protein is a disordered membrane phase-preferring protein.	
32	Amyloid precursor protein, although partially detergent-insoluble in mouse cerebral cortex, behaves as an atypical lipid raft protein. 1999 , 344 Pt 1, 23-30	33
31	Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. 1999 , 344 Pt 2, 461-7	49
30	Cholesterol decreases secretion of the secreted form of amyloid precursor protein by interfering with glycosylation in the protein secretory pathway. 2000 , 348 Pt 2, 307-13	30
29	Flavanols, mild cognitive impairment, and Alzheimer's dementia. 2008 , 1, 181-91	24
28	LRP-1 variation is not associated with risk of Alzheimer's disease. 2010 , 1, 104-13	8
27	Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. 2006 , 10, 247-54	74
26	CHOLESTEROL AND NEURONAL SUSCEPTIBILITY TO BETA-AMYLOID TOXICITY. 2010 , 5, 35-56	5
25	Impact of Methyl- β -Cyclodextrin and Apolipoprotein A-I on The Expression of ATP-Binding Cassette Transporter A1 and Cholesterol Depletion in C57BL/6 Mice Astrocytes. 2021 , 23, 93-98	

- 24 Axonal plasma membrane-mediated toxicity of cholesterol in Alzheimer's disease: A microsecond molecular dynamics study. **2021**, 281, 106718 0
- 23 An evidence-based review of neuronal cholesterol role in dementia and statins as a pharmacotherapy in reducing risk of dementia. **2021**, 1-18 0
- 22 Advances in Genetics and Epigenetic Alterations in Alzheimer's Disease: A Notion for Therapeutic Treatment.. **2021**, 12, 1
- 21 Mechanistic Link between Vitamin B12 and Alzheimer's Disease.. **2022**, 12, 2
- 20 Dementia in Diabetes mellitus and Atherosclerosis; Two Interrelated Systemic Diseases.. **2022**, 181, 87-87
- 19 A New Hypothesis for Alzheimer's Disease: The Lipid Invasion Model.. **2022**, 6, 129-161 0
- 18 Implications of Sphingolipids on Aging and Age-Related Diseases. **2022**, 2, 2
- 17 Profiling of circulating chromosome 21-encoded microRNAs, miR-155, and let-7c, in down syndrome.. **2022**, e1938 0
- 16 Cyclodextrins as promising therapeutics against cholesterol overload. **2022**, 927-967 0
- 15 Involvement of cholesterol and β amyloid in the initiation and progression of Alzheimer's disease. **2022**, 715-745
- 14 Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial function. **2022**, 825-851
- 13 Review of Drug Therapy for Peripheral Facial Nerve Regeneration That Can Be Used in Actual Clinical Practice. **2022**, 10, 1678
- 12 Effect of Cholesterol on C99 Dimerization: Revealed by Molecular Dynamics Simulations. 9, 1
- 11 Plasma high-density lipoprotein cargo is altered in Alzheimer's disease and is associated with regional brain volume. 0
- 10 Vitamin B12 Attenuates Changes in Phospholipid Levels Related to Oxidative Stress in SH-SY5Y Cells. **2022**, 11, 2574 0
- 9 Specific Mutations in the Cholesterol-Binding Site of APP Alter Its Processing and Favor the Production of Shorter, Less Toxic A β Peptides. **2022**, 59, 7056-7073 0
- 8 Assessment of cholesterol homeostasis in the living human brain. **2022**, 14, 0
- 7 Amyloid β Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer's Disease. **2022**, 23, 12092 0

- 6 Structural Determinant of β Amyloid Formation: From Transmembrane Protein Dimerization to β Amyloid Aggregates. **2022**, 10, 2753 1
- 5 The mevalonate suppressor β -tocotrienol increases AMPA receptor-mediated neurotransmission. **2022**, 14, 10
- 4 CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with early Alzheimer's disease. **2022**, 14, 10
- 3 Correlations between the NMR Lipoprotein Profile, APOE Genotype, and Cholesterol Efflux Capacity of Fasting Plasma from Cognitively Healthy Elderly Adults. **2023**, 24, 2186 0
- 2 Acute ACAT1/SOAT1 Blockade Increases MAM Cholesterol and Strengthens ER-Mitochondria Connectivity. **2023**, 24, 5525 0
- 1 Cellular cholesterol loss by DHCR24 knockdown leads to $A\beta$ production by changing APP intracellular localization. **2023**, 100367 0